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ABSTRACT 
The risk of cardiovascular diseases such as hypertension increases dramatically in 
postmenopausal women. During this natural deficiency of estrogen, hormonal replacement 
therapy (HRT) may potentially delay the onset of cardiovascular disorders. However, HRT 
has been reported to have carcinogenic side-effects and to actually increase the incidence 
of heart attack and stroke. In order to research for alternative therapies, selective estrogen 
receptor modulators (SERMs) have been developed. Raloxifene may replace H R T if 
outcomes of the ongoing clinical trials confirm its therapeutic value and safety. SERMs 
relax blood vessels in vitro and in vivo. However, the mechanisms involved are still not 
clear, particularly those in the coronary circulation are incompletely understood. On the 
other hand, nifedipine, a selective L-type voltage-sensitive Ca^ "" channel blocker that is 
widely used in the treatment of hypertension, could cause sudden cardiac death in patients 
with coronary artery disease through deleterious mechanisms. Finding novel Ca^ "" channel 
blockers with reduced side effects on the heart is in great need in medication. Cilnidipine, a 
unique blocker for both L_ and N_ type Ca^^ channels appears to offer clinical advantages 
over nifedipine because this blocker minimizes the baroreflex-mediated increase in 
sympathetic output to the heart by blocking the release of noradrenaline. However, the 
Ca2+ channel-independent vascular benefits are unknown. It is possible that cilnidipine 
could increase the bioavailability of nitric oxide (NO) by stimulating the N O production in 
the endothelium or by serving as an antioxidant agent, just like some dihydropyridine 
calcium antagonists. The present study aimed at examining the roles of endothelial N O and 
ion channels in the acute effects of tamoxifen, raloxifene, cilnidipine and nifedipine in 
isolated porcine left circumflex coronary arteries by using multiple techniques including 
isometric force measurement, Ca"^ fluorescence imaging and electrophysiology. 
The roles of vascular endothelium, inward-rectifier K+ (KIR) channel and 
sodium/potassium pump (Na+/K+-pump) in tamoxifen-induced relaxation were examined. 
Relaxation to tamoxifen was significantly attenuated upon removal of the endothelium in 
rings constricted by endothelin-1. Treatment with inhibitors of the NO-dependent pathway, 
NG-nitro-L-arginine methyl ester or ODQ, markedly attenuated the relaxation to a similar 
degree. On the other hand, tamoxifen-induced relaxation was reduced effectively by 
ouabain (Na+/K+-pump inhibitor) or BaCb (KIR channel blocker) with no additive effect. In 
coronary arteries without endothelium, the relaxation induced by sodium nitroprusside (a 
N O donor) was inhibited significantly by ouabain, but not by BaCb. The incubation in a 
K+-free Krebs solution (an ionic condition used to eliminate the activity of Na+/K+-pump) 
inhibited vasorelaxation to tamoxifen to a similar extent as the addition of ouabain. 
Raloxifene, the second-generation S E R M was investigated for its pharmacological 
action in coronary arteries. Raloxifene concentration-dependently suppressed contractile 
responses to U46619, endothelin-1，and serotonin in normal Krebs solution or to CaCb in a 
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Ca-^ -free, high K+-containing solution. In endo the 1 in-1-contracted rings, raloxifene 
produced the same relaxant effects in rings with and without endothelium. This effect was 
partially inhibited by either iberiotoxin, TEA+ or by elevated extracellular K^ (30 mmol/L 
K+ and 60 mmol/L K+). ICI 182,780 (estrogen receptor antagonist) had no effect on 
raloxifene-induced relaxation. In addition, raloxifene increased the outward Ca^ -^activated 
K+ (BKca) current, which was sensitive to inhibition by iberiotoxin. 
Raloxifene at therapeutic concentrations (1-3 nmol/L) did not cause relaxation, but 
such low concentrations enhanced endothelium-dependent relaxation to bradykinin or 
substance P in rings with endothelium without affecting endothelium-independent 
relaxation to sodium nitroprusside. It appears that raloxifene increased NO-dependent 
component of bradykinin-induced relaxation while the E D H F component was not affected. 
ICI 182,780 inhibited the synergistic effect between raloxifene and bradykinin. Estrogen at 
10 nmol/L also augmented relaxation to bradykinin in ICI 182,780-sensitive manner. 
Finally, the relaxant effects of dihydropyridine (DHP) calcium channel antagonists, 
cilnidipine and nifedipine were studied. Cilnidipine or nifedipine relaxed coronary arteries 
constricted by 60 mmol/L KCl with the former being slow-acting and the latter being more 
effective. In 30 mmol/L KCl-constricted rings, cilnidipine or nifedipine at 30 nmo/L 
induced greater relaxation in the presence of endothelium. Treatment with L-NAME or 
O D Q inhibited cilnidipine-induced relaxation to the same extent. Indomethacin was 
without effect. L-Arginine reversed the effect of L-NAME. In rings without endothelium, 
nitroprusside-induced relaxation was abolished by ODQ, but not by L-NAME. Cilnidipine 
did not influence endothelium-independent relaxation. Both cilnidipine and nifedipine at 
30 nmol/L stimulated a rise in the Ca""" level in native endothelial cells. 
In summary, the present study has provided several pieces of novel findings on the 
effects of S E R M s and DHPs in isolated porcine arteries. (1) Tamoxifen relaxed arteries via 
endothelial NO-dependent mechanism and endothelium-derived N O stimulate 
Na+-K+ATPase in vascular smooth muscle leading to vasorelaxation; this effect involves 
ICI 182,780-sensitive estrogen receptor, but not antagonism of Cd?^ influx; (2) raloxifene 
also relaxed coronary arteries through an endothelium-independent mechanism. It appears 
that raloxifene relaxed vascular smooth muscle by inhibiting Ca"^ influx and opening K+ 
channels and this effect is ICI 182,780-insensitive; (3) raloxifene at concentrations 
equivalent to plasma levels in postmenopausal women recording 60 mg/day raloxifene 
augmented endothelium (NO)-mediated relaxation to bradykinin and substance P and 
estrogen shared similar effect. This effect can be inhibited by ICI 182,780; (4) cilnidipine 
(a new D H P Ca^ "" channel antagonist) relaxes coronary arteries in part through endothelial 
NO-mediated mechanism related to increased Ca^^ levels in endothelial cells. The onset of 
relaxation was slower for cilnidipine compared with nifedipine. The results of the present 









調節劑（SELECTIVE ESTROGEN RECEPTOR MODULATORS, SERMS )的藥物正被開發 ° 有關 
SERMS的臨床試驗持續地顯示其臨床作用’也許可以替代HRT。SERMs能通過不同 






















昔芬（0.3 - 50 |imol/L )對血管的舒張作用被鉀括抗劑TEA+和Ibenotoxin (IBX)及高濃 




由U46619收縮的血管中，雷洛昔芬的臨床治療劑量（1 - 3 nmol/L)可提高BRADYKININ 
的血管舒張作用。跟雌二醇（3 - 10 nmol/L)對提高BRADYKININ的血管舒張作用一樣， 
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Chapter I - INTRODUCTION 
CHAPTER I 
Introduction 
1.1. Steroid Hormones 
Hormones are the chemical substances that possess specific regulatory effects on 
the reactivity of organs. These chemicals are divided into three groups based on their 
chemical structures and they are (i) steroid hormones, (ii) amino acid-related hormones, 
and (iii) peptides and protein hormones. In addition, their biochemistry, biosynthesis and 
metabolism are different. In mammalian system, six existing families of steroid hormones 
are classified on the structural and biological bases. They include estrogens, androgens, 
progestins, mineralocorticoids, glucocorticoids and vitamin D. 
All steroid hormones, which are lipids, are derived from cholesterol. They are 
present almost in all living organisms. Except for vitamin D, the basic structure of steroids 
has a cyclopentanoperhydrophenanthrene ring (Fig. 1.2). Cholesterol, as a precursor of 
several classes of steroid hormones synthesized in smooth endoplasmic reticulum (ER), 
makes these hormones non-polar and lipid soluble. Due to these properties, they can 
readily diffiise to bloodstream from their production cells via crossing the plasma 
membranes. A group of plasma transport proteins is responsible for transporting these 
steroids from bloodstream to their target cells. And, these steroids can be readily absorbed 
in gastrointestinal tract after oral administration. 
One of the steroid hormones, estrogen, is crucial to both male and female in various 
physiological processes. Estrogen is involved in growth, differentiation, and function of 
reproductive system. These include mammary glands, uterus, vagina, and ovaries in 
females; and testes, epididymis, and prostate gland in males. Furthermore, estrogen is 
anabolic in protein metabolism and water retention. Nevertheless, the major beneficial role 
played by estrogen in female becomes apparent once the dramatic fall in circulating 
estrogen occurs in female after menopause. The cessation of menstruation stops ovulation 
and cyclical elevation of estrogen and progesterone, but increases pituitary gonadotrophin 
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levels. These changes are always associated with a number of symptoms due to a reduction 
in the plasma estrogen levels. 
1.2. Estrogen Receptors 
Estrogen receptors (ERs) exist in various tissues including endothelial cells (Karas 
et aL, 1998) and vascular smooth muscle cells (Karas et aL, 1994; Makela et aL, 1999; 
Register & adams, 1998; Savolainen et aL, 2001). High concentration of ER is present not 
only in the mammary gland, endometrium, and hypothalamic area, but also in liver, 
immunoresponsive cells, and certain cancer tissues (Kangas, 1992). And the brief summary 
of their distribution is shown in Table 1.1. 
Estrogen receptor, which is defined as a ligand-dependent transcription factor, 
comprises a DNA-binding domain (DBD), a ligand-binding domain (LBD), an N-terminal 
constitutive activation function (AF-1) and a C-terminal hormone-dependent activation 
function (AF-2) domain as shown in Fig. 1.1. After binding by estrogen and subsequent 
receptor dimerization, ER modulates the rate of gene transcription by the interaction of 
D B D with estrogen response elements (ERE) in target gene promoter regions. D B D 
consists of two zinc fingers, which mediate receptor binding to an ERE in the promoter 
region of hormone-responsive genes. LBD, which contains two regions of sequence 
homology with other hormone receptors, is responsible for the hormone selectivity and 
specificity. AF-l is responsible for the activation of promoter-specific transcription 
independent on the presence of ligand, and AF-2 provides ligand-specific activation. Both 
AF-1 and AF-2 activate transcription in a cell and promoter context specific manner. 
In human, two isoforms of ER (ERa and ERP) exist. ERa (595 amino acids) has a 
longer amino acid chain than ER(3 (530 amino acids). These two ERs differ mostly in their 
N- and C- terminal domains, which has only 18% amino acid similarity in each region (Fig. 
1.1). This marked difference in N-terminal domain indicates distinct patterns of the 
transcriptional activation of different estrogen-responsive genes mediated by both ERa and 













































































































































































































































































































































































Chapter I - INTRODUCTION 
Tissue Distribution of Estrogen Receptor a and p Isoforms 
Tissues i ^ O E R P 
Blood vessel ^ 
Bone Z (Cortical) , (Cancellous) 
Brain Z (Hypothalamus) Z (Whole brain) 
Breast ^ (Elevated in cancer) Z 
^ 
Heart ^  
Immune � 
Liver Z (Mostly a isoform) Z 
Ovary ^ ^ 
Uterus — Z (Mostly a isoform) Z 
Table 1.1 
Tissue-specific distribution of estrogen receptors based on following studies (Bord et al., 
2001; Kuiper et al, 1997; Gustafasson, 1999). 
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1.3. Selective Estrogen Receptor Modulators 
Selective estrogen receptor modulators (SERMs), which are a group of compounds 
with diverse chemical structures, have agonistic and antagonistic effects of estrogen in a 
tissue-specific manner. Lack of steroid structure (hydrogenated 
cyclopentanoperhydrophenanthrene ring) does not prevent S E R M s from binding to ER 
because of the presence of a tertiary structure, which allows them to interact with ER. 
S E R M s are divided into several categories including (1) triphenylethylene derivatives, 
such as tamoxifen (Nolvadex®), (2) non-steroidal benzothiophene derivatives, such as 
raloxifene (Evista⑧）and (3) pure steroidal antiestrogens, such as Fulvestrant ICI 182,780 
(Faslodex®). The chemical structures of 17 -estradiol, raloxifene, tamoxifen and 
Fulvestrant ICI 182,780 are shown in Fig. 1.2 and Fig. 1.3. 
Unlike estrogens, SERMs exert both ER agonistic and antagonistic effects depending 
on target tissues or cell types. This unique tissue-specificity of SERMs has been widely 
recognized. For instance, clinically used SERMs such as raloxifene are estrogenic in bones 
and cardiovascular system, whilst they are anti-estrogenic in breast tissue and endometrium. 
Major actions of SERMs are summarized in Table 1.2. The aim of developing SERMs is to 
overcome the detrimental effects of hormone replacement therapy (HRT), while sharing 
the beneficial effects of HRT. Application of H R T in postmenopausal women has been 
questioned since publications of two large clinical trials (Hulley et aL, 1998; Rossouw et 
al” 2002), which showed no overall benefits for postmenopausal women. Instead, HRT 
caused a significant increase in the incidence of heart attack and stroke. As a result, search 
for alternative therapy such as SERMs has become trendy and necessary in women's 
health. 
1.3.1. Tamoxifen 
Tamoxifen is the first-generation SERM, which is used clinically in the treatment of 
breast cancer in postmenopausal woman over the past 20 years. It was first identified as a 
potential contraceptive in 1960s, from working as a contraceptive to now serving as the 
first line anti-breast cancer drug. Studies of its other biological activities have now been 
extended to the cardiovascular system. 
5 
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1.3.1.1. Cardiovascular Effects of Tamoxifen 
Tamoxifen has been reported to possess an estrogen-like cardioprotective effect in 
postmenopausal women. Reduced fatal myocardial infarction (MI) and reduced 
hospitalization rates in patients with MI were reported in two adjuvant therapy (with 
tamoxifen) trials (McDonald & Stewart, 1991; McDonald et aL, 1995). Moreover, another 
long-term adjuvant treatment with tamoxifen also led to a substantial reduction in cardiac 
morbidity in patients with early-stage breast cancer (Rutqvist & Mattsson, 1993). Besides, 
tamoxifen exerts a beneficial effect on both serum lipid profiles, including lowering the 
plasma levels of total cholesterol and low-density lipoprotein (LDL) (Love et aL, 1990; 
1991). Finally, tamoxifen reduces serum levels of several cardiovascular risk factors such 
as fibrinogen, homocysteine and plasminogen activator inhibitor-1 (Love et aL, 1994a; 
Grey et al, 1995; Cattaneo et al., 1998). 
1.3.1.2. Acute Vascular Effects of Tamoxifen 
Tamoxifen acutely relaxed rabbit coronary arteries in an endothelium- and nitric oxide 
(NO)- dependent manner since a reduced relaxation to tamoxifen was observed upon 
removal of the endothelium, and under the effect of N^-nitro-L-arginine methyl ester 
(L-NAME) (a competitive eNOS inhibitor) in arteries with endothelium. The endothelium 
(NO)-dependent effects of tamoxifen were likely mediated by estrogen receptors since the 
relaxant response to tamoxifen was antagonized by ICI 182,780 (non-selective estrogen 
receptor blocker). Tamoxifen also caused endothelium-independent relaxation of rabbit 
coronary arteries by acting on the vascular smooth muscle cells, but it shows no significant 
effect on calcium concentration-dependent contraction curves (Figtree et al, 2000). The 
results from Figtree's study (2000) in isolated arterial rings are apparently different from 
those obtained in single arterial myocytes. Tamoxifen reduced voltage-gated calcium 
currents recorded in rat aortic smooth muscle cell line (A7r5) (Song et al, 1996). In 
addition, both 17-estradiol (Han et al, 1995) and raloxifene (the second-generation 
SERM) (Figtree et al, 1999) relaxed blood vessels partly by inhibiting voltage-gated 
calcium channels in vascular smooth muscle cells. It is likely that tamoxifen may be 
6 
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fundamentally different from estrogen or raloxifene in causing vasorelaxation. Other 
proposed mechanisms for tamoxifen-induced vasorelaxation include inhibition of protein 
kinase C (Wickman & Vollrath, 2000) and inhibition of mitogen-activated protein kinase 
(MAPK) in rat aortic smooth muscle. Furthermore, both estrogen receptor and M A P K are 
involved in non-genomic relaxation induced by estrogen, resulting in reduced 
MAPK-mediated phosphorylation of caldesmon (the protein that binds to calmodulin) and 
consequently decreases the myofilament force sensitivity to calcium ions (Orshal et al., 
2004). Tamoxifen was shown to inhibit the activities of ERKl and ERK2 (Extracellular 
signal-regulated kinase) and p38 M A P K in both functional studies in rat aortic smooth 
muscle and colorimetric enzyme activity assay (Park et al., 2003). 
1.3.1.3. Chronic Vascular Effects of Tamoxifen 
Apart from the acute effects of tamoxifen, chronic effects of tamoxifen were also 
studied in rat blood vessels. In rat aorta without endothelium, chronic treatment with 
tamoxifen was shown to up-regulate the m R N A expression of voltage-gated Kvi.s channel 
and to down-regulate the m R N A expression of aicSubunit, the pore-forming region of the 
voltage-gated calcium channel in ovariectomized rats (Tsang et al., 2004c). A similar 
action of chronic 17(3-estradiol therapy was also observed on the m R N A expression of both 
KVI.5 channel and AIC subunit in aortas from ovariectomized rats (Tsang et al., 2004c). The 
ability to differentially regulate the m R N A expression of Kvi.s channel and aic subunit 
suggests that tamoxifen might reduce the augmented blood vessel tone in response to 
certain constricting agonists due to estrogen deficiency caused by ovariectomy by either 
reducing expression and/or function of L-type voltage-gated calcium channels or 
increasing expression and/or function of voltage-gated potassium channels. In contrast, 
chronic treatment with tamoxifen or estrogen did not alter the m R N A expression of both a-
and P-subunits of large-conductance calcium-activated potassium channels (BKca channels) 
(Tsang et al., 2004c). In another recent study on ovariectomized female rats chronically 
treated with tamoxifen and estrogen, either alone or in combination, it was found that 
tamoxifen, like estrogen, reduced the enhanced cerebrovascular tone following 
ovariectomy. Chronic treatment of tamoxifen was able to suppress contractions induced by 
endothelin-l or calcium chloride, but not by phenylephrine or U46619. In contrast, neither 
7 
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tamoxifen (10 nmol/L) nor estrogen (1 nmol/L) at such low concentrations could acutely 
inhibit cerebrovascular constriction to four constrictors (endothelin-1, calcium chloride, 
phenylephrine and U46619) (Tsang et al.，2004a). It appeared that tamoxifen might act as 
an estrogen agonist in the rat cerebral circulation because it did not antagonize the 
cerebrovascular effect of estrogen, nor induced a summative effect after combined 
therapies (Tsang et al.’ 2004a). 
1.3.1.4. Antioxidant Effects of Tamoxifen 
Tamoxifen was reported to reduce the concentration of an end product of lipid 
peroxidation, malondialdehyde, and to augment the levels of both non-enzymatic and 
enzymatic antioxidants, such as vitamins A, C, and E in postmenopausal women with 
breast cancer receiving tamoxifen therapy (Thangaraju et aL, 1994). Moreover, tamoxifen 
could scavenge hydroxyl free radicals in an in vitro study (Leguene et al., 2001). 
1.3.2. Raloxifene 
Raloxifene is a second-generation SERM, which was approved by F D A in late 1997, 
for the use in the prevention and treatment of osteoporosis in postmenopausal women 
(Saitta et al., 2001a). Raloxifene is currently being evaluated for its potentially beneficial 
effects in the cardiovascular system (Mosca et al., 2001). Among the health benefits, 
raloxifene acts as an estrogen-agonistic agent in bone (Delmas et al., 1997; Johnston et al., 
2000), lipid metabolism (Delmas et al., 1997; Walsh et al； 1998; de Valk-de Roo et al” 
1999), and in the central nervous system (Wu et aL, 1999). On the other hand, raloxifene 
may exert an estrogen-antagonistic effect on both breast tissue and uterine endometrial 
tissue (Saitta et aL, 2001b). 
1.3.2.1. Cardiovascular Effects of Raloxifene 
In both animal and clinical studies, raloxifene was reported to possess vascular 
beneficial effects similar to those of estrogen. In a previous study using cholesterol-fed 
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rabbits, raloxifene reduced aortic accumulation of cholesterol (Bjamason et al., 1997), 
suggesting a potential inhibitory action on the initiation and development of atherosclerosis. 
Randomized clinical trials showed similar favorable effects of raloxifene on lipid profile to 
those of estrogen, even though tamoxifen was slightly less effective as compared with 
estrogen. Raloxifene treatment reduced the total cholesterol and LDL cholesterol without 
affecting significantly high-density lipoprotein (HDL) cholesterol or triglycerides (Delmas 
et al., 1997; Draper et al., 1996). An increased LDL-cholesterol level was implicated in the 
formation of foam cells and atherosclerotic progression (Zuckerman et al., 1996). The 
LDL-lowering effect of raloxifene is another vascular benefit in its potential use against the 
development of atherosclerosis. Like estrogen, raloxifene also lowers the plasma 
concentrations of fibrinogen, plasminogen activator inhibitor-1 and homocysteine in 
postmenopausal women (Walsh et al., 1998; Mijatovic et al, 1998). All these favorable 
effects are likely to underlie the cardioprotective effect conferred by raloxifene especially 
in women after menopause. Given the benefits on several cardiovascular risk markers, the 
safety of using raloxifene is important. Neither histopathological evidence of endometrial 
stimulation nor increased risk of endometrial cancer was reported with the use of 
raloxifene. Instead, treatment of raloxifene actually reduced the risk of invasive breast 
cancer by approximately 76% (Cummings et al., 1999), and patients with breast cancer 
who had high levels of endogenous estrogen also benefited from raloxifene therapy 
(Cummings at al., 2002). To date, ongoing large-scale, randomized clinical trials including 
R U T H (Raloxifene Use for The Heart) study (Barrett-Connor et al., 1998; Mosca et al., 
2001; Mosca, 2001), M O R E (Multiple Outcomes of Raloxifene Evaluation) study (Ettinger 
et al., 1999; Agnusdei et al., 2000; Yaffe et cd., 2005), and C O R E (Continued Outcomes of 
Raloxifene Evaluation) study (Cummings et al., 2000) will determine whether raloxifene 
should become an alternative therapy to HRT in postmenopausal women when the ultimate 
outcomes of these trials are released. 
1.3.2.2. Acute Vascular Effects of Raloxifene 
In in vitro studies, raloxifene was shown to stimulate the production of N O in 
endothelial cells and this effect may result from either augmented eNOS enzymatic activity 
or increased protein expression of eNOS (Simoncini et al., 2002; Hisamoto et al., 2001; 
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Simoncini & Genazzani, 2000a; 2000b; Figtree et aL, 1999). Raloxifene relaxed rabbit 
coronary arteries via both endothelium-dependent and -independent mechanisms. The 
former is likely to be mediated by endothelial N O since eNOS inhibitor, L - N A M E 
inhibited raloxifene-induced endothelium-dependent relaxation component of relaxation 
(Figtree et al., 1999). It appears that raloxifene was more effective than estrogen in 
relaxing rabbit coronary arteries (Figtree et al., 1999). The endothelium-mediated relaxant 
effects of raloxifene seem to be mediated via ICI 182,780-sensitive estrogen receptor 
(Simoncini & Genazzani, 2000a; Figtree et al., 1999). An intracellular signaling 
mechanism has been proposed to explain the effect of raloxifene on endothelial cells. After 
the stimulation of ERa, raloxifene triggers a non-genomic estrogen receptor signaling 
process relating to activation of phosphatidylinositol 3-kinase (PI3K) and subsequent Akt 
that leads to a rapid activation of eNOS in human endothelial cell (Simoncini et al., 2002). 
Raloxifene treatment was associated with a positive modulation of endothelium-dependent 
vasodilatation and improved endothelial function (Colacurci et al., 2003). In a 
vasculopathic male rat model, the vascular effect of LY117018 (an analogue of raloxifene) 
was compared with that of 17/5-ethinyloestradiol. LY 117018 inhibited adrenergic 
vasoconstriction and lowered blood pressure probably through both NO-dependent and 
-independent mechanisms, and inhibited platelet aggregation via a NO-independent 
pathway (Russell et al., 2001). 
Raloxifene acts on vascular smooth muscle cells to cause relaxation. Raloxifene 
relaxed several blood vessels via inhibition of calcium influx through voltage-gated 
calcium channels in rabbit coronary arteries (Figtree et al., 1999), rat cerebral arteries 
(Tsang et al., 2004b), rat intrarenal arteries (Leung et al, 2005), and rat pulmonary arteries 
and veins (Chan et aL, 2005). In single arterial myocyte isolated from rat cerebral arteries, 
raloxifene reversibly inhibited L-type voltage-gated calcium currents (Tsang et aL, 2004b). 
Besides, both LY 117018 and estrogen were reported to indirectly inhibit the vascular 
calcium channels in rat aorta and LY 117018 was more potent than estrogen in their 
calcium channel antagonistic properties (Cohen et al., 1996). 
1.3.2.3. Chronic Vascular Effects of Raloxifene 
Chronic treatment with raloxifene improved endothelium-derived N O release by the 
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up-regulation of the eNOS m R N A expression (Rahimian et aL, 2002). Spontaneously 
hypertensive rats normally show impaired endothelial function due to the reduced 
production of NO; chronic raloxifene treatment significantly increased the release of N O 
(Wassmann et al., 2002). Similarly, chronic subcutaneous or oral administration of 
LY117018 enhanced the release of N O from rat aortic endothelial cells (Rahimian et aL, 
1997). Moreover, in human endothelial cell, LY117018 inhibited the m R N A expression of 
vascular cell adhesion molecule-1 (VCAM-1), suggesting that LY 117018 may have an 
anti-atherogenic effect (Simoncini et al,, 1999). On the other hand, raloxifene inhibited 
migration of the human aortic vascular smooth muscle cells without affecting smooth 
muscle cell proliferation (Wierniki et al., 1996). 
1.3.2.4. Ovariectomy and Raloxifene Treatment 
Raloxifene decreased systemic vascular resistance, increased coronary and uterine 
blood flow in ovariectomized sheep (Clark et al” 2000). Ovariectomy in rats (Pavo et al., 
2000) resulted in the down-regulation of vascular constitutive N O synthase (eNOS) and 
this may account for the increased constriction sensitivity to vasopressin. Raloxifene 
treatment normalized the vessel sensitivity to vasopressin (Pavo et al., 2000). Moreover, a 
study using ovariectomized ewes (Zoma et aL, 2000) showed that short-term treatment 
with raloxifene increased both uterine and coronary blood flow, and this effect was similar 
to that of estrogen. The effect of raloxifene was partially reversed by the systemic 
administration of L - N A M E (a N O S inhibitor) (Zoma et al” 2000), suggesting a possible 
role of N O in raloxifene-induced vascular effects in vivo. Nevertheless, it is still unknown 
whether the vascular effects of raloxifene in animal blood vessels can be repeated in 
human vessels. Randomized studies using aged ovariectomized ewes showed that 
raloxifene was more effective than estrogen in causing coronary arterial dilatation, while 
raloxifene did not affect vascular remodeling (Gaynor et al., 2000). 
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Chemical structure of 17P-Estradiol and ICI 182,780 
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Major Actions of SERMs in Target Tissues 
First-generation Second-generation Pure Ideal 
Sites Estrogen s^RMs SERMs anti-estrogen SERMs 
？ , Tamoxifen Raloxifene ICI 164,384��� 
Estradiol “ 
Breast + __ _ . . . -
Bone + + + - + 
Cardiovascular 
. o t 
system + + 十 . 卞 
Cholesterol 
metabolism + + + ？ + 
Coagulation 
(DVT, PE) + + + ? _ 
Endometrium + . (Partially) - - -
Hot flashes + + _ ？ + 
Vagina + + . ？ + 
D V T 二 Deep vein thromboses 
PE = Pulmonary emboli 
？ = Not known or not reported (SERM action not yet well established) 
+ == Agonistic (defined in relation to the action of estrogen 二〉estrogenic) 
- 二 Antagonistic (= anti-estrogenic), more negative sign means higher potency! 
(1) Preclinical and clinical studies have shown that fulvestrant and ICI 164,384 are more 
potent than tamoxifen in inhibiting the growth of breast cancer cells (Elkak & Mokbel, 
2001) 
Table 1.2 
Major actions of SERMs in target tissues 
(The table is modified from Selective Estrogen Receptor Modulators (SERMs), edited by 
Anthony M, Dunn B.K and Sherman S, published in Ann N YAcadSci 2001;949:383.) 
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1.4. Mechanism of Action of SERMs 
Regarding the classical action of estrogen, the uncoupled nuclear estrogen receptor is 
located in the nucleus of the target cell in an inactive form. Upon binding to an agonist, e.g. 
17(3-estradiol, the physicochemical properties of the estrogen receptor alters，which allows 
the estrogen receptor dimer to interact with specific D N A sequences (ERE) within the 
promoters of responsive genes (Gruber et al., 2002). The DNA-bound estrogen receptor 
can then regulate the target gene transcription either negatively or positively. The effects of 
estrogenic agonist are mediated by both ERa and ERP, which belong to a superfamily of 
nuclear hormone receptors and share high homology in their D B D (-95%) but less in their 
L B D (-58%) (Kuiper et al., 1996). In different tissues or cells, both ligand-binding 
specificity and the distribution of ERa and ERj3 are different (Kuiper et al” 1997). This 
may explain the unique tissue specificity of SERMs. 
The unique pharmacology of SERMs is generally explained by three interactive 
mechanisms: 1) differential estrogen receptor expression in a given target tissue, 2) 
differential estrogen receptor conformation alteration upon ligand binding, and 3) 
differential expression and binding to the estrogen receptor of co-regulator proteins (Fig. 
1.4). 
Estrogen-targeting cells contain varying concentrations of homodimers of one or two 
estrogen receptor isoforms and heterodimers. A distinct action of either isoform of the 
estrogen receptor is demonstrated in estrogen receptor null mice (Kuiper et al., 1997; 
Couse & Korach，1999). ERa always acts as an activator, whilst ER(3 is able to inhibit the 
action of ERa by forming a heterodimer with ERa. The relative expression levels of the 
two isoforms will affect the cellular responsiveness to estrogen (Hall & McDonnell, 1999; 
Pettersson et al., 2000). In a cell line (HepG2 cells) transfected by an ERE-based reporter, 
tamoxifen is a partial agonist of ERa and a pure antagonist of ERP (Hall & McDonnell, 
1999). When both isoforms are co-expressed in the same cell type, the net cellular response 
to a ligand is likely to depend on the ratio of expression (Hall & McDonnell, 1999; Jones et 
al” 1999). ERa and ERP are differentially expressed in various tissues including breast, 
liver, bone, cardiovascular system, gastrointestinal, and urogenital tract (Gustafsson, 1999); 
this may explain differential responses to a given S E R M among different organs and 
tissues. 
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Some protein crystallographic studies showed the distinct conformational change in 
the transactivation domain of the L B D (Brzozowski et al, 1997), upon the binding of 
estrogen, tamoxifen (Shiau et al” 1998), raloxifene (Paige et al., 1999)，or the pure 
anti-estrogen ICI 164,384 (Pike et aL, 2001). For example, estrogen and raloxifene bind to 
the same site within the core of LBD, but with different binding modes (Brzozowski et al., 
1997). The binding of estrogen causes helix 12 to seal the ligand inside the hydrophobic 
pocket of the L B D and this activates the complex by permitting the binding of coactivators 
and AF-2. On the contrary, the binding of raloxifene prevents helix 12 from sealing the 
hydrophobic pocket, which repositions helix 12 in order to block the binding of 
coactivators. As a result, gene transcription is prevented (Park & Jordan, 2002). 
More than twenty coregulating proteins have been found, which bind to estrogen 
receptors and modulate their function. Each of them acts on transcriptional regulation 
either positively (as a coactivator) or negatively (as a corepressor) (Jepsen et al., 2000; 
McKenna et al., 1999; Norris et al., 1999; Smith et al, 1997). Depending upon the 
uniqueness of the receptor conformation at change induced by ligand binding, varying 
combinations of coregulator proteins interact with the estrogen receptor and modulate its 
function in different ways. The absolute and relative expression levels of coregulator 
proteins vary among different types of estrogen target cells (McKenna et al., 1999). 
According to a recent study, tamoxifen and raloxifene, which are estrogen-antagonistic in 
breast tissues, act on the mammary cells by recruiting corepressors to estrogen-receptor 
target promoter. In contrast, tamoxifen, which is estrogen-agonistic in the endometrium, 
acts on the endometrial cells by recruiting coactivators to the estrogen-receptor target 
promoter, whereas raloxifene shows a neutral effect on endometrium. Moreover, the 
tamoxifen-ERa complex has been found to activate gene transcription by tethering to 
promoters, which do not contain estrogen response elements through protein-to-protein 
contacts with other DNA-bound transcription factors (Chaidarun & Alexander, 1998). The 
agonistic effect of tamoxifen depends on a higher concentration of a key coactivator called 
steroid receptor coactivator-1 (SRC-1) in the endometrium (Lonard et al., 2004). As a 
result, varied local concentrations of coregulator proteins may contribute to the tissue 
specificity of SERMs. 
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1.5. Effects of Functional Endothelium and Nitric Oxide 
As early as in 1980, Furchgott R (1998 Noble prize laureate) first reported that 
endothelium-derived relaxing factor (EDRF) as a signaling molecule was released from 
vascular endothelial cells of freshly isolated blood vessels (Furchgott et al., 1980). This 
relaxing factor was later proposed to be N O (Palmer et al., 1987; Ignarro et al., 1987). N O 
is now generally accepted as E D R F in many vascular beds. N O is synthesized from the 
terminal guanidino nitrogen atom(s) of L-arginine, and eNOS mediates this enzymatic 
process, which could be inhibited by L-arginine analogues such as 
N^-monomethyl-L-arginine (L-NMMA). Studies using L - N M M A reveal that the constant 
tonic generation and release of N O in the endothelium contribute to maintain vascular tone, 
and thus control blood pressure. Various ligands, pharmacological agents, and shear stress 
can modulate the role of vascular endothelial cells in the regulation of vasomotor activity. 
In response to agonists that stimulate an increase in intracellular calcium levels in the 
endothelium, endothelium can also produce relaxing factors other than NO, including 
prostacyclin (PGI2) and a series of yet to be determined factors called endothelium-derived 
hyperpolarizing factors (EDHFs). Apart from liberating relaxant factors, endothelial cells 
can synthesize and release constricting factors including endothelin-1, thromboxane A2 and 
.free radicals. These factors are usually called endothelium-derived constricting factor 
(EDCF). EDCFs counterbalance the EDRF-mediated vascular benefits, causing impaired 
endothelium-dependent relaxation, which is normally characterized as endothelial 
dysfunction. Endothelial dysfunction is characteristic of essential hypertensive patients 
(Panza et al., 1990; Taddei et al” 1993; Panza et al., 1993; Taddei et al., 1997a). 
Endothelial dysfunction is a functional and reversible alteration of endothelial cells 
resulting from the attenuated production and release of N O (Panza et al” 1993). Thus, 
many antihypertensive drugs lower blood pressure by increasing bioavailability of 
endothelial NO. 
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1.6. Dihydropyridine (DHP) Calcium Channel Antagonists 
Since the development of the first-generation therapeutic D H P {e.g., nifedipine) 
(Bossert & Vater, 1971), D H P calcium antagonists have become one of the major drug 
classes in the treatment of angina pectoris and hypertension. These drugs bind to the a] 
subunit of the voltage-sensitive calcium channels in vascular smooth muscle cells 
(Catterall & Striessnig, 1992; Hofmann et al., 1990). The blockade of long-lasting L-type 
calcium channel in smooth muscle inhibits calcium influx, thereby attenuating 
vasoconstriction and reducing blood pressure. However, the adverse effects of DHPs cause 
concerns in patients with coronary artery disease. The short-acting and fast-onset D H P {e.g. 
nifedipine) induce powerful and rapid vasodilatation, which lead to a 
baroreceptor-mediated reflex increase in sympathetic tone. The increased activity of 
adrenergic system and the renin-angiotensin system resulted in tachycardia, increased 
myocardial contractility and stroke volume. (Kimichi & Lewis, 1991). The Secondary 
Prevention Reinfarction Israel Nifedipine Trial 2 (SPRINT 2) study reported that early 
administration of nifedipine increased the risk of mortality in patients with suspected acute 
myocardial infarction (Goldbourt et al., 1993). Therefore, several other D H P calcium 
antagonists such as amlodipine have been developed with improved therapeutic safety, 
including gradual onset of vasodilatation, longer acting and reduced reflex tachycardia 
(Haria & Wagstaff，1995). 
1.6.1. Development of Newer Generation of Dihydropyridines 
Amlodipine that is shown to overcome the clinical disadvantages of the fast-acting 
nifedipine, attenuates sympathetic nerve hyperactivation and induces relatively 
slow-developing hypotensive effects (Haria & Wagstaff, 1995). Cilnidipine (FRC-8653), 
which inhibits both L-type and N-type calcium channels (Yoshimoto et al., 1991), was first 
studied in neuronal cells {e.g. rat dorsal root ganglion neurons) for its N-type calcium 
channel antagonistic action (Fujii et al., 1997; Uneyama et al., 1997; 1998). In in vitro 
experiments, cilnidipine blocks catecholamine secretion from pheochromocytoma PC 12 
cell elicited by high KCl (Uneyama et al., 1998) or in arterial walls evoked by field 
electrical stimulation (Nakashima et al., 1991). Oral administration of cilnidipine lowered 
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blood pressure without increasing catecholamine levels or heart rate in spontaneously 
hypertensive rats. Inhibition of hypotension-induced baroreflex activity is likely to 
attribute to the attenuation of sympathetic neurotransmission by blocking N-type 
voltage-sensitive calcium channel (Hosono et al., 1995). 
1.6.2. Effects of Dihydropyridines on Vascular Endothelium (I) 
In addition to L-type calcium channel antagonistic effects, DHPs were also reported to 
modulate the endothelial function (Kojda et al, 1990). Vascular endothelium does not 
express L-type calcium channel (Adams et al., 1989); therefore, DHPs act on endothelial 
cells via virtually different mechanisms. Kojda et al (Kojda et al., 1990) was the first group 
to demonstrate an endothelium-dependent effect of DHPs, and they reported that 
nitrendipine-induced relaxation was attenuated upon the removal of endothelium. In the 
presence of methylene blue (a guanylate cyclase inhibitor), the concentration-response 
curve of nitrendipine-induced relaxation was shifted to the right in PGF2a-preconstricted 
porcine coronary and basilar arteries (Kojda et al., 1990). Soluble guanylate cyclase (GC) 
is the specific target of N O and it mediates formation of cyclic G M P (Forstermann et al., 
1994; Moncada et al., 1991). Likewise, treatment withN^ -nitro-L-arginine (L-NNA) (a 
competitive inhibitor of endothelial NOS) caused a rightward shift of 
concentration-response curve to nitrendipine in porcine coronary arteries, basilar arteries 
and tail arteries (Gunther et al； 1992). Calcium channel blockade-independent effect on 
the endothelium was also extended to other D H P calcium antagonists including amlodipine 
(Berkels et al； 2004), isradipine, lacidipine (Godfraind & Salomone, 1996), nifedipine 
(Berkels et cd., 2001a) and nisoldipine (Berkels et al., 2001b). In isolated perfused guinea 
pig mesenteric vascular beds and in Langendorff perfused guinea pig hearts, both 
nitrendipine and nifedipine increased flow of perfusate, which was blocked by L-NNA (a 
N O synthase inhibitor) (Berkels et al., 1999a). In open-chest in vivo dog, both nifedipine 
and benidipine increased coronary blood flow, which was attenuated by L - N A M E (a N O S 
inhibitor) (Kitakaze et al., 1999; 2000). Nifedipine was shown to mediate coronary 
vasodilatation via NO/bradykinin-dependent pathway. In an in vivo heart ischemia model, 
benidipine or nifedipine limited the infarct size by the mechanisms associated with N O and 
bradykinin (Kitakaze et al, 1999; Asanuma et al, 2001a; 2001b). 
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1.6.3. Effects of Dihydropyridines on Vascular Endothelium (II) 
Besides functional studies, direct (chemiluminescence and electrochemical electrodes) 
and indirect (cyclic G M P assay, nitrate/nitrite assay and oxy-hemoglobin assay) methods 
were used to determine the modulation of endothelial N O release by DHPs. By 
oxy-hemoglobin assay, nitrendipine was found to induce a concentration-dependent N O 
release from the porcine vascular bed and bovine endothelial cell cultures, which was 
sensitive to inhibition by N O S blocker (Gunther et ai, 1992; Salameh et al., 1996). By 
nitrate assay, amlodipine (another widely used D H P calcium antagonist) released N O from 
canine coronary microvessels and macrovessels, which was abrogated by a bradykinin 
receptor blocker and N O S inhibitor (Zhang & Hintze, 1998). The NO-releasing effect of 
amlodipine was shown to involve stereoisomerism, in which R-enantiomer but not 
S-enantiomer was responsible for the release of N O (Zhang et al., 2002). In addition, 
nisoldipine and nifedipine enhanced the N O release from endothelial cells of various 
vascular beds including rabbit aorta and porcine aorta as measured using a NO-sensitive 
electrode (Berkels et al., 1999b; 2001a; 2001b). This technique also confirmed a direct N O 
releasing effect of lacidipine in rat aorta (Crespi et al, 2001). In addition, Bay K 8644 (a 
D H P calcium channel agonist) produced similar effects, suggesting that D H P could 
produce additional vascular benefit by releasing N O in endothelial cells (Berkels et al., 
1999b), By placing a highly sensitive electrochemical micro-sensor onto endothelial cell 
surface, nifedipine at therapeutic concentration stimulated the release of N O and scavenged 
O2' in endothelial cells (Brovkovych et al., 2001). 
1.6.4. Effects of Dihydropyridines on Nitric Oxide Synthase (NOS) 
Increased bioavailability of N O by DHPs was reported to be attributed to (1) an 
enhanced N O S expression, (2) an enhanced N O S activity, and (3) a prolonged N O half-life. 
Nifedipine and felodipine but not verapamil (a phenylalkylamine class L-type calcium 
channel antagonist) were reported to enhance N O S activity and N O S protein expression in 
rat and human cultured endothelial cells (Ding & Vaziri, 1998; 2000). In L-NAME-induced 
hypertensive rats, the left-ventricular N O S activity and endothelial N O S (eNOS) m R N A 
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were increased after treatment with amlodipine (Kobayashi et aL, 1999a). In a 
renovascular hypertensive rat, chronic treatment with benidipine increased the N O S 
activity and m R N A expression in left ventricle (Kobayashi et al” 1999b), and these results 
were consistent with the findings obtained from aortas in lacidipine-treated salt-loaded 
Dahl-S rats (Crespi et al., 2002). 
1.6.5. Clinical Studies of Dihydropyridines 
Atherosclerosis is related to increased levels of oxidized LDL and reduced N O 
bioavailability characterized as endothelial dysfunction. Both experimental (Mason, 2001; 
Pitt et al., 2000; Fleckenstein-Grun et al； 1992; 1994) and clinical (Waters et al., 1990; 
Lichtlen et al., 1990; Bellosta & Bernini, 2000; Zanchetti et al., 2002; Simon & Levenson， 
2002; Rachmani et al., 2002; Park et al., 2002; Motro & Shemesh, 2001; Mason, 2001; 
2002; Pitt et al., 2000; Brown et al., 2000) studies have reported that several D H P calcium 
antagonists {e.g. amlodipine, lacidipine, lercanidipine and nifedipine) attenuated the 
formation of atherosclerotic lesions. In hypercholesterolemic patients with impaired 
vasodilation, 6-week chronic treatment with Nifedipine GITS (long-acting 
gastrointestinal-transport system with slow release preparation) was found to restore 
5-HT-induced vasodilatation together with a reduction in endothelial superoxide generation; 
the vasodilatation was initially impaired in hypercholesteremic patients (Verhaar et al., 
1999). Likewise, chronic treatment with isradipine improved acetylcholine-mediated 
vasodilatation in hypercholesteremic patients (Bracht et al., 2001). In essential 
hypertensive patients, chronic treatment with amlodipine (On et aL, 2002), isradipine 
(Perticone et al., 1999), lacidipine (Taddei et al., 2001) or lercanidipine (Taddei et al., 2003) 
resulted in a significant improvement of endothelium-dependent vasodilatation to 
acetylcholine and bradykinin, whereas endothelium-independent vasodilatation remained 
unchanged. 
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Fig. 1.6 
General chemical structure of 1,4-dihydropyridine calcium antagonist 
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1.7. Vascular Ion Channels 
Vascular tone determines blood flow resistance, regulates blood pressure, and 
controls blood distribution in different tissues and organs. In vascular smooth muscle cells, 
ion channels play a crucial role in the vascular tone regulation. Vascular smooth muscle 
expresses different types of ion channels that help maintain the resting membrane potential 
and calcium homeostasis. These channels include calcium channels, potassium channels, 
and chloride channels. Extracellular calcium ions enter the vascular smooth muscle cells 
via three pathways (L-type voltage-sensitive calcium channels, receptor-operated calcium 
channels and store-operated calcium channels). Membrane potential is a key regulator of 
calcium influx through controlling the opening and closure of voltage-sensitive calcium 
channels, while the basal activities of various types of potassium channels determine the 
resting membrane potential. There are four types of potassium channels that have been 
identified in vascular smooth muscle cells and they include ATP-sensitive K+ (KATP) 
channel, large conductance Ca^ -^activated K+ (BKca) channel, voltage-activated K+ (Kv) 
channel, and inward rectifier K+ (KIR) channel, which are involved in the regulation of 
vascular tone to various degrees depending on vascular beds (Jackson et al., 1997; Jackson 
et al., 1998a; Jackson et cd., 1998b; Jackson & Blair, 1998). Membrane hyperpolarization 
of vascular smooth muscle cell due to activation of potassium channels normally 
inactivates voltage-sensitive calcium channels, reduces calcium influx and thus causes 
vasodilatation. In contrast, the closure of potassium channels usually causes membrane 
depolarization, which opens voltage-gated calcium channels, and leads to vasoconstriction. 
BKca channels are readily activated by an increase in intracellular calcium concentrations 
and/or membrane depolarization (Carl et al., 1996; Nelson & Quayle, 1995). In resistance 
arterioles displaying myogenic tone, the activity of BKca channels contributes to the 
resting membrane potential. Blockade of these channels by iberiotoxin or tetraethyl 
ammonium ions leads to membrane depolarization and vasoconstriction (Nelson et aL, 
1990; Brayden and Nelson, 1992; Nelson et al., 1995; Nelson & Quayle, 1995). BKca 
channels may play a negative feedback role to inhibit vasoconstriction and vasospasm in 
small arteries. 
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1.8. Objectives of The Present Study 
Cardiovascular diseases including coronary heart disease and hypertension are 
common in postmenopausal women. Hormone replacement therapy (HRT), which was 
widely used to relieve postmenopausal symptoms, has been recently found to actually 
increase the risk of heart attack and stroke (Hulley et al., 1998; Rossouw et al.，2002). 
Besides, estrogen is carcinogenic in breast and uterine tissues. As a result, selective 
estrogen receptor modulators (SERMs) including tamoxifen and raloxifene were developed. 
The vascular benefits of S E R M s could lead to novel therapeutic strategies to hypertension, 
stroke and atherosclerosis in postmenopausal women. On the other hand, dihydropyridine 
(DHP) is clinically used for the treatment of hypertension. The reported detrimental effect 
of nifedipine in patients with heart diseases causes serious safety concern. The 
development of new-generation safer DHPs is in urgent need. Amlodipine and cilnidipine, 
the new-generation DHPs possess N-type calcium channel blocking activity, which could 
reduce reflex tachycardia, thus provide advantages over nifedipine. However, the 
underlying mechanisms of the new drugs are still incompletely understood. 
The objectives of the present study were to investigate: 
1. The role of endothelium, estrogen receptor, NO, inwardly-rectifier potassium channels, 
and Na+-K+ ATPase in tamoxifen-induced acute vasorelaxation in porcine coronary 
arteries. 
2. The role of endothelium, estrogen receptor, and calcium-activated potassium channels 
(Kca) in raloxifene-induced relaxation in porcine coronary arteries. 
3. The synergistic effects between therapeutic concentrations of raloxifene and 
endothelium-dependent dilators in mediating vasodilatation in porcine coronary 
arteries. 
4. The role of endothelium and endothelial N O in cilnidipine and nifedipine-induced 
vasorelaxation in porcine coronary arteries. 
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CHAPTER II 
Materials and Methods 
2.1. Tissue Preparation 
2.1.1. Preparation of The Porcine Left Circumflex Coronary Arteries 
The pig hearts were obtained from a local slaughterhouse in Sheung Shui, Hong 
Kong, immersed immediately in freshly prepared ice-cold and oxygenated Krebs-Henseleit 
solution, and then brought back to the laboratory. After the surrounding connective tissues 
were carefully removed, each porcine left circumflex coronary artery was cut into ring 
segments, 3-mm in length under a dissection microscope. 
2.1.2. Removal of Functional Endothelium 
In some experiments, the endothelial layer was mechanically removed by gently 
rubbing the luminal surface of arterial rings back and forth several times with small plastic 
tubing. The integrity of the endothelium or its functional removal was confirmed by the 
presence or absence of a relaxant response (over 85%) to bradykinin (50 nM) in 
pre-constricted rings. 
2.1.3. Organ Bath Setup 
After coronary artery preparation, each arterial ring was mounted between two 
stainless wire hooks in a 10-ml organ bath filled with freshly prepared and oxygenated 
Krebs solution. The upper wire was connected to a force-displacement transducer (Ft-03, 
Grass Instrument Co, USA) and the lower one was fixed to the bottom of the organ bath. 
Changes in isometric force were continuously recorded by Mac lab software (version 3.5) 
and data was stored for later analysis. Figure 2.1 illustrates the organ bath setup used for 
measurement of isometric vessel tension. 
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Figure 2.1 
A set-up used for of measurement of changes in isometric force of arterial rings 
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The rings were bathed in pre-warmed, oxygenated Krebs solution. The temperature of 
bathing solution was maintained at 37。C by heating pump (Polyscience, USA) connected 
to a circular heat exchanger and was continuously monitored with a miniature thermometer 
probe (Edale Instruments Ltd., Cambridge, England). The bathing solution was gassed 
constantly with 95% O2 and 5% CO2 to give a pH value of approximately 7.4. 
Replacement with a pre-warmed and pre-oxygenated Krebs solution was achieved via an 
outlet in each organ bath to a waste container. 
All ring segments were placed under an optimal resting tension of 15 mN, which was 
determined previously by length-tension relationship experiments and allowed to 
equilibrate for 60 min in Krebs solution at 3 7� C . Baseline tone of blood vessels was 
re-adjusted whenever necessary. 
2.1.4. Isometric Force Measurement 
After 60-min equilibration, each ring was first constricted by a single concentration 
U46619 (30 nM) to test its contractility and the integrity of endothelium was then verified 
by over 85% relaxation to bradykinin (50 nM) in rings with endothelial cells. Successful 
removal of the endothelium was substantiated by the lack of the relaxation to bradykinin 
(50 nM). Rings with and without endothelium were used in this study. Thereafter, rings 
were washed several times in Krebs solution until baseline tone was restored. The detailed 
description of experimental protocols and procedures are presented in relevant chapters. 
2.2. In situ Endothelial [Ca!.�丨 Imaging 
2.2.1. Preparation of Porcine Left Circumflex Coronary Arteries 
Porcine left circumflex coronary artery was dissected out and cleaned of the 
adventitial adipose and surrounding connective tissue, and subsequently cut into ring 
segments (3-mm length) for in situ Ca^^ imaging studies. The rings were fluorescently 
labeled by incubation for 1 hr with 10 juM Fura-2 AM, 0.025% Pluronic F-127 and 1 m M 
probenacid (to prevent Fura-2 secretion) in Krebs-Henseleit solution at room temperature. 
Extracellular Fura-2 A M was washed away in Krebs-Henseleit solution. The rings then 
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were perfused for 20 min with Krebs-Henseleit solution at a rate of 2 ml/min (at 37 °C) to 
allow intracellular cleavage of Fura-2 A M into active Fura-2 by esterases. 
2.2.2. Setup For/w situ Endothelial [Ca^+L Imaging 
The basic experimental setup of endothelial [Ca"^ ], imaging was modified from the 
setup described by Huang et aL, (2000). After the Fura-2 loading, artery rings were 
longitudinally cut opened and pinned by insect pins onto a block of silicone elastomer 
(Sylgard, World Precision Instruments, Inc., Florida, USA), which was fixed onto the base 
plate of the custom-made flow chamber. The base plate was then covered with a gasket 
and cover glass (24 m m X 32 m m ; thickness: no. 1; Menzel-Glaser, Germany), and affixed 
by screws. There was a 1-mm gap between the vessel luminal surface and the cover glass 
to allow free flow passage. After vessel mounting, the flow chamber was placed on an 
inverted microscope and perfused by Krebs-Henseleit solution, which was maintained by a 
dual automatic chamber system temperature controller (Warner Instrument Inc., CT, USA). 
The solutions perfused under a constant flow of 2 ml/min which was controlled by a 
six-channels perfusion pump (205S; Watson Marlow Corp., CT, USA) and a basic 
mini-valve perfusion system with six-channels (Warner Instrument Inc., CT, USA). 
The specimen was illuminated on the stage of the 1X70 Olympus microscope 
(Olympus America Inc., NY，USA), fitted with a 20X Olympus water immersion objective 
(0.50W, U M P L A N F L , Olympus America Inc., NY, USA), using a Polychrome IV light 
source (TILL Photonics GmbH, Grafelfmg, Germany). Fura-2 loaded vessels were 
alternatively excited at 340 and 380 nm, and images of the respective 510-nm emissions 
were collected in 1-sec intervals using MetaFluor v4.6 software (Universal Imaging Corp., 
West Chester, PA, USA). The emitted light was transmitted to the collecting device and 
then to a cooled charge coupled device (CCD) camera (Photometries Quantix, Roper 
Scientific, Inc., NJ, USA). Illumination through the Polychrome IV light source and 
acquisition by the C C D camera were controlled by MetaFluor software v4.6 (Universal 
Imaging Corp., West Chester, PA, USA). Video frames containing images of cell 
fluorescence were digitized at a resolution of 512 horizontal X 480 vertical pixels. Imaging 
analysis was also performed with a MetaFluor imaging system (Universal Imaging, West 
Chester, PA, USA). After background subtraction, the fluorescence ratio (F340/F380) was 
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obtained by dividing, pixel by pixel, the 340 nm image by the 380 nm image. Changes in 
this ratio were used to express changes in the intracellular Ca^^ concentration to eliminate 
potential artifacts due to variations in cell thickness, intracellular dye distribution or 
photobleaching. 
2.3. Electrophysiological Measurement of BKca Current 
2.3.1. Enzymatic Dissociation of Coronary Artery Smooth Muscle Cells 
The enzymatic method used to isolate single vascular smooth muscle cells from 
porcine coronary arteries is described in detail in Chapter 4. 
2.3.2. Electrophysiological Measurement 
Experimental protocols for electrophysiological measurement of BKca currents on 
single vascular smooth muscle cells are described in detail in Chapter 4. 
2.4. DPPH Free Radical Scavenging Assay 
Possible free radical scavenging effects of DHPs, raloxifene and estrogen were 
examined as previously described (Blois, 1958). a-TocopheroI (vitamin E) was used as a 
reference antioxidant. In brief, 0.5 m L of methanol containing different concentrations of 
drugs was mixed in a test tube with 2.5 m L of methanol containing 75 fimol/L 
2,2-diphenyl-1 -picrylhydrazyl (DPPH). DPPH is a stable free radical with a deep purple 
color in ethanotic solution and a typical absorbance at 517 nm, but becomes pale yellow 
when trapped by an antioxidant. The reaction mixture was kept in dark at room 
temperature for 90 min and the absorbance at 517 nm was thereafter measured. The free 
radical scavenging activity was approximated using the following equation: 
DPPH scavenging activity (%) = [A-O^b-灿/A x 100 
where 礼 is the absorbance of the incubation DPPH solution without drug, is the 
absorbance of the incubation mixture containing DPPH and drug, and A^ is the absorbance 
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of the blank solution (methanol) with DPPH. 
2.5. Solutions and Drugs 
2.5.1. Drugs, Chemicals and Enzymes 
Chemicals Description Solvent Source 
A23187 Calcium ionophore D M S O Tocris 
Acetylcholine hydrochloride Muscarineic receptor agonist; H2O Sigma 
Endothelium-dependent 
vasodilator 
Actinomycin D R N A synthesis inhibitor D M S O Sigma 
Aminoguanidine hemisulfate Inducible nitric oxide synthase H2O Tocris 
inhibitor 
4-aminopyridine Kv channel blocker D M S O Sigma 
A M T hydrochloride Inducible nitric oxide synthase H2O Tocris 
(AMT-HCl) inhibitor 
Apamin ‘~ SKca channel inhibitor D M S O Sigma 
Barium chloride KIR channel blocker H2O Merck 
Bradykinin acetate Endothelium-dependent H2O ICN 
vasodilator 
Butylated hydroxytoluene Free radical scavenger D M S O Sigma 
(BHT) 
Cilnidipine "L-type V G C C blocker D M S O 
Charybdotoxin (CTX) IKca and BKca channel inhibitor H2O Sigma 
Cycloheximide Protein synthesis inhibitor D M S O Sigma 
9,ll-Dideoxy-lla,9a Thromboxane A2 analogue, D M S O Sigma 
-epoxymethano-prostaglandin vasoconstrictor 
F2a(U46619) 
2,2-Diphenyl-l -picrylhydrazyl Stable free radical Methanol Sigma 
(DPPH) 
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Dimethyl sulphoxide (DMSO) Organic solvent for drugs - Sigma 
17P-estradiol Female steroid hormone D M S O Sigma 
Endothelin-1 (ET-1) Selective ETA endothelin H ^ Tocris^ 
receptor agonist 
Glibenclamide KATP channel blocker D M S O Sigma 
Hypoxanthine Substrate of xanthine oxidase D M S O Sigma 
Iberiotoxin Specific BKca channel blocker H2O Sigma 
ICI 182,780 Estrogen receptor antagonist D M S O Tocris 
Indomethacin Non-selective cyclooxygenase D M S O Sigma 
inhibitor 
L-Arginine Nitric oxide precursor H2O Sigma 
Nifedipine Putative L-type V G C C blocker D M S O Sigma 
N'^ -nitro-L-arginine methyl Non-specific nitric oxide H2O Sigma 
ester (L-NAME) synthase inhibitor 
Nco-propyl-L-arginine Selective inhibitor of nNOS H2O Tocris 
lH-[l,2,4]oxadizolo[4,3-a] Guanylate cyclase inhibitor D M S O Sigma 
quinoxalin-l-one (ODQ) 
Ouabain Na+-K+-ATPase inhibitor D M S O S i g m a 
Phorbol-12,13-diacetate PKC activator D M S O Sigma 
(PDA) 
Raloxifene HCl Selective estrogen receptor D M S O Eli Lilly 
modulator (SERM) & Co. 
Serotonin (5-HT) Neurotransmitter H2O RBI 
Sodium nitroprusside (SNP)Exogenous nitric oxide donor H2O Sigma 
Tamoxifen citrate Selective estrogen receptor D M S O Sigma 
modulator (SERM) 
Tetraethyl ammonium Non-selective BKca channel H2O Sigma 
chloride (TEA.) blocker 
Tertiapin-Q KIR channel blocker H2O Tocris 
The drug stock solution was normally prepared and stored in distilled water or DMSO, and 
further diluted in Krebs' solution or D M S O to a desired concentration. 
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2.5.2. Solutions Used in Force Measurement 
Composition of modified Krebs-Henseleit solutions (KHS) 
iKrebs- iKrebs |30 m M K + | 6 0 m M K + | 6 0 m M K+ 
Unit (mM) 2+ 
Henseleit (Ca^ "'-free) (Ca^ -^free) 
TT9 TT9 ^ ^ ^ 
N a H C 0 3 ^ 25 Ys ^ ^ 
MgCl2-6H20 1 1 1 1 1 
m 4?7 Jd ^ ^ 
KH2P04 L2 L2 Tl T2 72 
C ^ ^ 0 ^ ^ 0 
D-glucose i n T u TTTi T u 11.1 
The solutions were freshly prepared before each experiment. The pH value of the solutions 
were maintained at pH 7.4 by continuously bubbling the solution with 95% O2 plus 5% 
CO2 at 37。C 
2.6. Statistical Analysis 
Statistical significance was analyzed by two-tailed student's t test for comparison of pECso, 
pD2 and Emax values or by one-way A N O V A followed by student-Newman-Keuls test when 
more than two groups were compared. P < 0.05 was considered as statistically significant. 
All results were expressed as mean 土 S.E.Ms of n determination. More detailed statistical 
analysis was described in the following result chapters. 
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CHAPTER III 
Tamoxifen-Induced Endothelial Nitric Oxide-Dependent 
Relaxation in Porcine Coronary Arteries via Ouabain- and BaCl!-
Sensitive Mechanisms 
3.1. Abstract 
This study was designed to investigate the relaxant action of tamoxifen and the 
mechanisms involved in porcine coronary arteries. Porcine left circumflex coronary arteries 
were isolated and changes in isometric tension were measured with Grass force transducer. 
in endothelial cells of intact arteries was determined by a calcium fluorescence imaging 
technique. Tamoxifen caused coronary artery relaxation that was primarily dependent on the 
presence of the endothelium and this effect was completely antagonized by ICI 182,780. 
Tamoxifen-induced endothelium-dependent relaxation was almost abolished by treatment with 
N^-nitro-L-arginine methyl ester (L-NAME) or lH-[l,2,4]oxadizolo[4,3-a]quinoxalin-l-one 
(ODQ), and L-arginine antagonized the effect of L - N A M E . Indomethacin had no effects. 
Tamoxifen failed to relax high KCl-contracted rings. Tamoxifen-induced relaxation was 
attenuated by treatment with charybdotoxin (CTX) plus apamin, ouabain, BaCl], tertiapin-Q, 
or by the incubation in a K+-free solution, but not by glibenclamide. Tamoxifen triggered 
extracellular Ca^^-dependent increases in endothelial [Ca�.]” Ouabain or the incubation in a 
K+-free solution but not BaCb inhibited endothelium-independent relaxation to sodium 
nitroprusside. In conclusion, the present results showed that tamoxifen caused mainly 
endothelium-dependent relaxation, and endothelial nitric oxide (NO) was the primary 
mediator. NO-dependent response may causally result from elevated in endothelial 
cells. N O derived from endothelial cells activates Na+-K+-ATPase in vascular smooth muscle, 
leading to relaxation. This study suggests the potential use of tamoxifen in the treatment of 
cardiovascular diseases associated with diminished N O release, such as atherosclerosis, as 
demonstrated in clinical studies. 
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3.2. Introduction 
Tamoxifen, a synthetic non-steroidal anti-estrogen (the first-generation selective 
estrogen receptor modulator, SERM)，is used primarily in the treatment of breast cancer in 
w o m e n (Fisher et al., 2000). Clinical investigations of tamoxifen for breast cancers suggest 
that tamoxifen could also exert estrogen-like cardiovascular protective effects (McDonald and 
Steward, 1991; McDonald et al., 1995). Tamoxifen therapy improves endothelial function in 
postmenopausal w o m e n (Stamatelopoulos et al., 2004) and in men with coronary artery 
disease (Clarke et aL, 2001). 
Animal studies support an estrogenic activity of tamoxifen in the vascular system. 
Chronic tamoxifen treatment reduced constrictive responses to endothelin-1 and CaCl! (Tsang 
et al； 2004a), and to phenylephrine (Thorin et al., 2003) in cerebral arteries from 
ovarietomized rats. Tamoxifen inhibited voltage-gated Ca^^ currents in aortic smooth muscle 
cells (Song et al., 1996) and chronic tamoxifen therapy attenuated the m R N A expression of 
the aic subunit of the voltage-gated Ca^^ channel in aortas from ovariectomized rats (Tsang et 
al., 2004b). Tamoxifen acutely relaxed mammalian blood vessels but the role of endothelium 
is controversial. Tamoxifen inhibited rabbit coronary artery tone involving estrogen receptor-
dependent endothelial N O release (Figtree et al., 2000), while endothelium-independent 
relaxation to tamoxifen was described in porcine coronary arteries (Hutchison et al., 2001). At 
least three mechanisms have been proposed to explain tamoxifen-induced endothelium-
independent relaxation in blood vessels from different species, including (i) contribution of 
ATP-sensitive K+ channel activation in porcine coronary arteries (Hutchison et al,, 2001), (ii) 
inhibition of protein kinase C in rabbit cerebral arteries (Wickman and Vollrath, 2000), and 
(iii) inhibition of mitogen-activated protein kinase in rat aortas (Park et al., 2003). It appears 
that the mechanisms responsible for tamoxifen-induced vasorelaxation may depend on the 
species under study. 
The present study with the use of porcine coronary arteries suggests a new mechanism 
accounting for tamoxifen-induced acute vasorelaxation. The results showed that tamoxifen 
caused mainly endothelium-dependent relaxation and endothelial N O was the primary 
mediator. NO-dependent response may causally result from elevated [Ca2+]i in endothelial 
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cells. N O derived from endothelial cells activates Na+-K+-ATPase in vascular smooth muscle, 
leading to relaxation. In contrast, tamoxifen did not affect high KCl-induced contraction, 
suggesting that voltage-sensitive Ca^^ channels may not be inhibited by tamoxifene in porcine 
coronary artery smooth muscle cells. This study indicates the potential use of tamoxifen in the 
treatment of cardiovascular diseases associated with diminished N O release, such as 
atherosclerosis. 
3.3. Methods and Materials 
All experiments described in this study were in accordance with institutional 
guidelines. This investigation conformed to the Guide for the Care and Use of Laboratory 
Animals published by the U S National Institute of Health (NIH Publication No. 85-23, revised 
1996). 
3.3.1. Vessel Preparation 
The pig hearts were obtained fresh from a local slaughterhouse in Hong Kong. The 
hearts were placed on a dissecting plate containing ice-cold Krebs solution. Krebs solution 
contained (in mmol/L): 119 NaCl, 4.7 KCl, 2.5 CaCb, 1 MgCh, 25 NaHCOs, 1.2 KH2PO4, and 
11 D-glucose. After fatty connective tissues were trimmed off, the left circumflex coronary 
artery was cut into several ring segments of 3 m m in length. Each ring was mounted in an 
organ bath. The bathing solution was continually oxygenated with 95% O2 - 5 % CO2 and 
maintained at 37 (pH: 7.3 - 7.5). The ring was stretched to the optimal tension of 15 m N 
and then allowed to equilibrate for about 90 min before the start of the experiment. In some 
rings, the endothelial layer was removed by gently rubbing the luminal surface with forceps 
tip. Removal of the functional endothelium was confirmed by the lack of a relaxant response 
to 50 nmol/L bradykinin. Each experiment was performed on rings prepared from different 
pigs. 
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3.3.2. Isometric Force Measurement 
Thirty min after setting up in organ baths, each ring was initially contracted by 30 
nmol/L U46619 and subsequently relaxed by 50 nmol/L bradykinin to confirm the presence of 
a functional endothelial layer if over 85% relaxation was obtained. Rings were then washed 
several times in pre-warmed Krebs solution until baseline tone was restored. High KCl 
solution was prepared by replacing an equivalent amount of NaCl in order to maintain 
constant ionic strength. 
Cumulative concentration-dependent effects of tamoxifen were studied in rings with 
and without endothelium contracted by endothelin-1 or by elevated extracellular K C L The 
initial experiments showed that tamoxifen-induced relaxation was almost abolished in rings 
without the endothelium. Therefore, the first set of experiments was designed to examine the 
roles of endothelium-derived relaxing factors. After confirming the presence of a functional 
endothelium, rings were incubated for 30 min with each of the following inhibitors [100 |iM 
N^-nitro-L-arginine methyl ester (L-NAME), 3 ^ imol/L 1H-[ 1,2,4]oxadizolo[4,3-a]quinoxalin-
1-one (ODQ)，3 ^imol/L indomethacin, or charybdotoxin (CTX) plus apamin, each at 50 
nmol/L] before the addition of endothelin-1. Once a steady vessel tension was obtained, 
tamoxifen was added cumulatively to the bathing solution. To further confirm the role of N O , 
the effect of L-arginine (500 |imol/L) was tested on L-NAME-induced inhibition. 
To elucidate the possible involvement of estrogen receptors, rings were treated with 1 
|imol/L ICI 182,780 (a classical estrogen receptor antagonist) before testing the relaxant effect 
of tamoxifen. In addition, the effects of 1-hr incubation with actinomycin D (a R N A synthesis 
inhibitor) or cycloheximide (a protein synthesis inhibitor) were also studied on tamoxifen-
induced relaxation. 
Since tamoxifen-induced relaxation was inhibited by C T X plus apamin and eliminated 
in 60 mmol/L K+-contracted rings, indicating an involvement of EDHF-like factors. The 
effects of BaCli and tertiapin-Q [putative inwardly rectifier K+ (KIR) channel blockers], 
iberiotoxin [large-conductance Ca^^-activated K+ (BKca) channel blocker] and ouabain (Na+-
K+ pump inhibitor) were examined. Rings with endothelium were exposed to each of these 
inhibitors for 30 minutes before studying the relaxant effect of tamoxifen. Besides, rings were 
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also co-treated with iberiotoxin plus ouabain prior to contraction to endothelin-1. The 
amplitude of initial tone was similar by varying the endothelin-1 concentration. 
In order to determine whether endothelium-derived N O could activate vascular smooth 
muscle Na+-K+ pump, BKca channels, or KIR channels, these inhibitors were examined on 
endothelium-independent relaxations to sodium nitroprusside (a N O donor) in rings without 
endothelium. The relaxant effects of tamoxifen, sodium nitroprusside, or nifedipine were also 
examined in K+-free bathing solution, an ionic condition that abolishes the influence of the 
Na+-K+ pump activity. 
3.3.3. In situ Endothelial Imaging 
Porcine circumflex coronary artery rings were fluorescently labeled by incubation with 
10 i^mol/L of Fura-2 A M , 0.025% Pluronic F-127 and 1 mmol/L probenacid (to prevent Fura 
2 secretion) in Krebs solution for 1 hr at 22 Extracellular Fura-2 A M was washed away 
with Krebs solution. The vessel rings were then perfused for 20-23 min with Krebs solution at 
a rate of 2 ml/min (at 37 °C) to permit intracellular esterases to cleave intracellular Fura-2 A M 
into active Fura-2. 
The basic setup for endothelial imaging was modified as described by Huang et 
al., (Huang et al., 2000). Briefly，after the Fura-2 loading, the rings were longitudinally cut 
open and pinned down onto a block of silicone elastomer, which was fixed onto a base plate of 
the custom-made flow chamber. The base plate was then covered with a gasket and cover 
glass (24 m m X 32 mm), and affixed by screws. There was a 1-mm gap between the vessel 
luminal surface and cover glass for free flow passage. After mounting, the flow chamber was 
placed on an inverted microscope and perfused with Krebs solution at 37 °C at a constant rate 
of 2 ml/min maintained by a six-channel perfusion pump. The specimen was illuminated on 
the stage of the 1X70 Olympus microscope, fitted with a 20X Olympus water immersion 
objective using a Polychrome IV light source. Fura-2 loaded vascular tissues were 
alternatively excited at 340 and 380 nm, and images of the respective 510-nm emissions were 
collected at every 1-second interval using MetaFluor v4.6 software (Universal Imaging Corp., 
USA). The emitted light was transmitted to the collecting device and then to a cooled charge 
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coupled device (CCD) camera. Illumination through the Polychrome IV light source and 
acquisition by the C C D camera were controlled by MetaFluor software v4.6. Video frames 
containing images of cell fluorescence were digitized at a resolution of 512 horizontal X 480 
vertical pixels. Imaging analysis was also performed with a MetaFluor imaging system 
(Universal Imaging, USA). After background subtraction, the fluorescence ratio (F340/F380) 
was obtained by dividing, pixel by pixel, the 340 n m image by the 380 n m image. Changes in 
this ratio reflected changes in to eliminate potential artifacts caused by variations in 
cell thickness, intracellular dye distribution or photobleaching. 
3.3.4. Chemicals 
Bradykinin, 9,11-dideoxy-l la,9a-epoxy-methanoprostaglandin Fia (U46619), N -
nitro-L-arginine methyl ester (L-NAME), 1H-[ 1,2,4]oxadizolo[4,3-a]quinoxalin-1 -one (ODQ), 
L-arginine, indomethacin, tamoxifen, endothelin-1, charybdotoxin (CTX), iberiotoxin (IBX), 
apamin, tertiapin-Q, ouabain, sodium nitroprusside (SNP), were purchased from Sigma 
(USA). ICI 182,780 (Tocris, UK). Stock solutions were prepared in D M S O for indomethacin, 
tamoxifen, estrogen, ICI 182,780 and glibenclamide and kept at -20 Desired dilution was 
made before experiments. D M S O (0.1% v/v) did not cause relaxation in endothelin-1 or KCl-
contracted rings. 
3.3.5. Data Analysis 
Data are mean 士 S.E.Ms and n refers to the number of artery rings studied from 
different pigs. Several rings prepared from the same artery were examined in parallel. The 
relaxant responses were calculated as percentage reduction of the constrictor-induced tone in 
each ring. Curves were analyzed by non-linear curve fitting using Graphpad software (Version 
3.0) and statistical difference between concentration-response curves were analyzed by two-
way A N O V A followed by Bonferroni post-tests. The negative logarithm of the relaxant 
concentration that produced half of the maximal relaxation (pDi) was approximated. P values 
less than 0.05 was regarded as statistically significant. 
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3.4. Results 
3.4.1. Relaxant Responses 
Traces in Fig. 3.1a show that tamoxifen relaxed rings with endothelial cells, contracted 
by endothelin-1 and U46619 with similar relaxing sensitivity and potency (p/^ 2: 4.84 土 0.06 
and 4.78 士 0.04, P < 0.05, Fig. 3.1b&c). In contrast, tamoxifen did not relax rings contracted 
by 60 mmol/L K C l (Fig. 3.1). 
Functional removal of endothelial cells markedly reduced the relaxation to tamoxifen 
(Emax： 83.2 士 3.70/0 with endothelium and 24.7 士 8.8o/o without endothelium, P < 0.001, Fig. 
3.2a). The remaining relaxation of rings without endothelial cells was unaffected by IBX (data 
not shown). Treatment with ICI 182,780 antagonized the relaxation to tamoxifen in rings with 
endothelium but it did not effect relaxations of rings without endothelial cells (Fig. 3.2b). 
3.4.2. Effects of Inhibitors of NO-Dependent Relaxation 
Markedly reduced relaxation in rings without endothelial cells suggested a primary 
contribution of endothelium-derived relaxing factors to tamoxifen-induced coronary artery 
relaxation. Treatment of rings with endothelium with L - N A M E or O D Q almost abolished the 
relaxant effect of tamoxifen (Fig. 3.2c) and L - N A M E and O D Q were equi-effective. Exposure 
to L-arginine, the precursor of N O biosynthesis, partially antagonized the inhibitory effect of 
L - N A M E (Fig. 3.2c). In contrast, treatment of intact rings with indomethacin did not modify 
the relaxant responses to tamoxifen (Fig. 3.2d), thus ruling out the involvement of 
vasorelaxing prostanoids. 
3.4.3. Effects of Putative K+ Channel Blockers 
The relaxant responses to tamoxifen were significantly inhibited by treatment with 
C T X plus apamin, but to a lesser degree as compared with those in L-NAME-treated rings 
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(Fig. 3.3). Combined treatment with L - N A M E , C T X plus apamin did not cause further 
inhibition (Fig. 3.3). 
3.4.4. Effects of Ouabain, Removal of Extracellular K+ ions and BaCh 
The role of Na+-K+-ATPase in tamoxifen-induced relaxation was assessed by treating 
the rings with ouabain or by the incubation in a K+-free solution. Ouabain reduced the relaxant 
effect of tamoxifen and combined treatment with ouabain and BaCb did not produce an 
additive effect (Fig. 3.4a). However, ouabain and BaCl] were equi-effective (Fig. 3.4a). 
Tertiapin-Q (another putative inhibitor of inward rectifier K+ channels) attenuated tamoxifen-
induced relaxation to the same extent as BaCl] (Fig. 3.4b). 
3.4.5. SNP-Induced Relaxation 
In rings without endothelial cells, SNP induced relaxation with pZ)� of 5.47 士 0.69. 
This relaxation was abolished by O D Q and attenuated by ouabain (Fig. 3.4c) but not by BaCl� 
or tertiapin-Q at concentrations that inhibited tamoxifen-induced relaxation in rings with 
endothelial cells (Fig. 3.4d). 
Removal of extracellular K+ ions also inhibited tamoxifen-induced relaxation in rings 
with endothelial cells (Fig. 3.5a) and SNP-induced endothelium-independent relaxation (Fig. 
3.5b). The effects of ouabain and zero extracellular K+ were similar (Fig. 3.5a&b). In 
contrast, nifedipine relaxed endothelin-1 -contracted rings and this effect was unaffected by 
ouabain or removal of extracellular K+ ions (Fig. 3.6). 
3.4.6. Effects of Actinomycin D and Cycloheximide 
Treatment with either actinomycin D (10 j^mol/L) or cycloheximide (10 juimol/L) did 
not affect tamoxifen-induced relaxation in rings with endothelium (Fig. 3.7). 
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3.4.7. Relaxant Effect of 17B-Estradiol 
For comparison, 17B-estradiol also caused concentration-dependent relaxation in rings 
contracted by endothelin-1 and the relaxations were similar in rings with and without 
endothelial cells (Fig. 3.8a). Treatment with 1 j^mol/L ICI 182,780 attenuated relaxation to 
17B-estradiol (Fig. 3.8b). Unlike tamoxifen, 17B-estradiol could reduce contraction induced by 
60 mmol/L K C l and this relaxation was slightly inhibited by 1 ^ imol/L ICI 182,780 (Fig. 3.8c). 
Treatment with ouabain (100 jj,mol/L) did not influence the relaxation to estradiol (Fig. 3.8d). 
3.4.8. Effects on Endothelial [Ca!.]! in Isolated Coronary Arteries With Endothelium 
Fluorescence images from individual living endothelial cells in the cut-open rings with 
endothelium were clearly visible (Fig. 3.9a&b) and signals were absent upon removal of the 
endothelium. The was elevated by the addition of substance P or bradykinin only in 
endothelium-intact arteries (data not shown). Fig. 3.9c shows that perfusion of tamoxifen 
triggered a rise in [Ca^ J^j. Fig. 3.9d shows that the augmentation of calcium by tamoxifen was 
sensitive to 1 fimol/L ICI 182,780. 
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Fig. 3.1. (a) Representative traces showing the relaxing effect of tamoxifen on porcine isolated 
coronary arteries with endothelium contracted by endothelin-1 (ET-1) or U46619, but not by 
60 mmol/L KCl. (b) Concentration-response curves for tamoxifen in rings contracted by the 
three different constrictors and (c) Emax values for tamoxifen-induced relaxation. Results are 
mean 士 S.E.Ms of 8-12 experiments. Statistical difference between high KCl and other groups 
is indicated by*** (P< 0.001) 
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Fig. 3.2. (a) Concentration-response curves for tamoxifen-induced relaxation in rings with (+ 
Endo) and without (- Endo) endothelium, (b) Inhibitory effect of ICI 182,780. (c) Inhibition of 
tamoxifen-induced relaxation by L - N A M E and O D Q in rings with endothelium and partial 
antagonism of L-arginine on L-NAME-induced effect, (d) The lack of effect of indomethacin. 
(d) Results are mean 士 S.E.Ms of 6-7 experiments. Statistical difference is indicated by *** {P 
< 0.001) compared with control curve. 
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Fig. 3.3. Inhibitory effects of C T X plus apamin or in combination with L - N A M E in rings with 
endothelium. Results are mean 士 S.E.Ms of 6-7 experiments. Statistical difference is indicated 
by *** {P < 0.001) compared with the control curve. 
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Fig. 3.4. Effects of ouabain and BaCh, alone or in combination (a), and tertiapin-Q (b) on 
tamoxifen-induced relaxation in rings with endothelial cells. Effects of ouabain and O D Q (c), 
or of BaCh and tertiapin-Q (d) on sodium nitroprusside (SNP)-induced relaxation in rings 
without endothelium. Results are mean 士 S.E.Ms of 6-7 experiments. Statistical difference is 
indicated by *** (P < 0.001) as compared with the control curve. 
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Fig. 3.5. Reduced relaxation in a K+-free bathing solution to tamoxifen (with endothelium, a), 
sodium nitroprusside (SNP, without endothelium, b). Results are mean 士 S.E.Ms of 5-6 
experiments. For comparison, the effect of ouabain was included in both graphs. Statistical 
difference {？ < 0.001) as compared with the control curve. 
48 
Chapter III — TAMOXIFEN 
§ ? • ] S ^ - End。 
I ^ 5 0 - T 
0 LLJ n-
DC： o U ^ C o n t r o l (+ KCI) 
§；；；；/ + Control (-KCI) 丄 
- 5 0 」 + Ouabain (+KCI) 
I 1 1 1 
- 9 - 8 - 7 - 6 
Nifedipine (log M) 
Fig. 3.6. The lack of effect of either ouabain or the removal of extracellular K+ solution on 
nifedipine-induced relaxation in rings without endothelium. Results are mean 士 S.E.Ms of 5 
experiments 
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Fig. 3.7. The lack of effects of actinomycin D (10 jumol/L) and cycloheximide (10 |_imol/L) on 
tamoxifen-induced relaxation in rings with endothelium. Results are mean 士 S.E.Ms of 7-8 
experiments. 
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Fig. 3.8. (a) Similar relaxations induced by 17B-estradiol in rings with and without 
endothelium, (b) Inhibitory effect of 1 }imol/L ICI 182,780 on tamoxifen-induced relaxation in 
rings with endothelium contracted by ET-1 (b) or 60 m M KCl (c). The lack of effect of 100 
l^mol/L ouabain on estrogen-induced relaxation (d). Results are mean 士 S.E.Ms of 5 
experiments. Statistical difference is indicated by *** {P < 0.001) compared with the control 
curve. 
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Fig. 3.9. The stimulatory effects of tamoxifen (30 jimol/L) at 0 min (a) and 40 min (b) after 
perfusion with tamoxifen in normal Krebs-Henseleit solution on endothelial calcium levels in 
situ in cut-open rings with endothelium. Time-dependent increase to in response to 
tamoxifen (c). Augmentation of calcium is sensitive to 1 jimol/L ICI 182,780 (d). Results are 
mean 士 S.E.Ms of 5 experiments from different pigs 
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3.5. Discussion 
The main findings of the present investigation include: (i) tamoxifen-induced 
endothelium-dependent relaxation in isolated porcine coronary arteries involved ICI 182,780-
sensitive estrogen receptors; (ii) upon stimulation by tamoxifen, endothelium-derived N O 
activated Na+/K+ ATPase in vascular smooth muscle, which was sensitive to ouabain and 
removal of extracellular K+ ions (an ionic condition that eliminates the influence of Na+/K+ 
ATPase) and this effect involved NO/cyclic G M P signaling pathway; and (iii) tamoxifen-
induced NO-dependent effect was causally caused by increased in native endothelial 
cells in intact coronary arteries in situ. 
N O , one of the most important endothelium-derived regulators of vascular tone and 
arterial blood pressure relaxes vascular smooth muscle cells via cyclic GMP-mediated 
mechanism. The results of the present investigation clearly point to a positive role of 
endothelial N O in the relaxation to tamoxifen in porcine coronary arteries. First, removal of a 
functional endothelium markedly attenuated tamoxifen-induced relaxation; the maximal 
relaxation was reduced from 83.2 土 3.7o/o to 24.7 士 8.8o/o. Second, tamoxifen-induced 
relaxation was sensitive to inhibition by pharmacological inhibitors of the NO/cyclic G M P -
dependent pathway. Treatment with L - N A M E or O D Q induced similar degree of reduction in 
tamoxifen-induced relaxation. The reduced relaxation after blockade of NO/cyclic G M P 
signaling pathway was similar to that obtained in rings without endothelium. Treatment of 
arterial rings with L-arginine, the precursor of N O synthesis, prevented L-NAME-induced 
inhibition of relaxation. In contrast, relaxing prostanoids are not involved since indomethacin 
(an inhibitor of cyclooxygenase) was without an effect. 
The present results showed that C T X plus apamin also inhibited tamoxifen-induced 
relaxation, albeit to a lesser degree as compared the effect of L - N A M E , suggesting that 
CTX/apamin-sensitive K+ channels are involved in the stimulation of N O production and 
release in response to tamoxifen since the inhibitory effect is similar in rings treated with L-
N A M E alone or in combination with C T X plus apamin. It is unknown whether tamoxifen 
could activate CTX/apamin-sensitive K+ channel on the endothelium, resulting in an increase 
in [Ca2+]i. 
53 
Chapter III — TAMOXIFEN 
The relaxant effect of tamoxifen was abolished by ICI 182,780 suggesting that the 
relaxation is likely to be mediated by ICI 182,780-sensitive estrogen receptor. In contrast, 
neither actinomycin D (an inhibitor of R N A synthesis) nor cycloheximide (an inhibitor of 
protein synthesis) affected tamoxifen-induced relaxation, indicating that tamoxifen exerts a 
non-genomic action on endothelial cells of porcine coronary arteries. The results are consistent 
with a previous study using pig proximal coronary arteries (Hutchison et al., 2001). However, 
the present study contrasts Hutchison's study in that tamoxifen did not relax 60 mmol/L KCl-
contracted coronary artery rings, while Hutchison et al reported a concentration-dependent 
relaxation to tamoxifen in high KCl-contracted rings. This discrepancy may be caused by 
different segments of porcine coronary arteries used by the two studies. Tamoxifen was also 
shown to cause an endothelial N O - and estrogen receptor-dependent relaxation in rabbit 
coronary arteries with little effect on CaCl2-induced contraction in a depolarizing solution 
(100 mmol/L KCI) (Figtree et al., 2000). 
The biosynthesis of N O from its precursor L-arginine is a Ca^^-dependent process 
catalyzed by eNOS. Various endothelial NO-dependent vasodilators stimulate the N O release 
by increasing endothelial [Ca^ J^j. Our study demonstrates that tamoxifen, like bradykinin, 
acutely caused a rise in in native endothelial cells in intact coronary arteries. A n 
increased C a� . influx may play a causal role in tamoxifen-induced N O release of endothelial 
cells. 
Another novel finding from the present study is ouabain- and BaCl2-sensitive 
mechanisms, Na+-K+-ATPase, are involved in the endothelial NO-dependent relaxation to 
tamoxifen based on the following observations in comparison with SNP, the N O donor. First, 
both ouabain (an inhibitor of Na+-K+-ATPase) and BaCli (an inhibitor of inwardly rectifying 
K+ channels in low micromolar concentrations) attenuated tamoxifen-induced relaxation to the 
same extent and combined treatment with both inhibitors did not cause additive effect. 
Second, tertiapin Q (another inhibitor of inwardly rectifying K+ channels) and BaCl� had 
similar inhibitory effects. Third, the relaxation to SNP in rings without endothelium was 
inhibited only by ouabain but not by BaCh or tertiapin Q. Fourth, the addition of ouabain 
caused small contraction (0.41 土 0.05 g, n=8), suggesting a basal activity of Na+-K+-ATPase 
in arteries. Finally, the removal of extracellular K+ ions from bathing solution reduced 
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tamoxifen-induced relaxation to the same degree as did ouabain in the presence of 
extracellular K+ ions. Likewise, S N P induced less relaxation after the incubation with a K+-
free solution, which was comparable with the magnitude of relaxation in normal Krebs 
solution added with ouabain. It was demonstrated before that SNP relaxed piglet mesenteric 
arteries partly through the activation of Na+-K+-ATPase (Cogolludo et al., 2001). The present 
results in conjunction with others suggest that in addition to the regulation of vascular tone, 
evidence exists that N O also plays a role in the control of basal Na+-K+-ATPase activity in 
arterial tissues (Gupta et al., 1994; Gupta et al., 1996). Although cyclic GMP-independent 
mechanisms have been reported (Goud et al., 1999), the present results indicate that N O -
induced stimulation of ouabain-sensitive Na+-K+-ATPase is likely mediated via cyclic G M P 
signaling pathway since O D Q , a selective inhibitor of soluble guanylate cyclase, nearly 
abolished the relaxing effect of tamoxifen in rings with endothelium and the relaxation to SNP 
in rings without endothelium. Since B a C h or tertiapin Q did not inhibit SNP-induced 
relaxation, indicating that the BaCb-sensitive site may be located on the endothelium of the 
arteries when relaxed by tamoxifen. While the ouabain-sensitive site is likely present on 
vascular smooth muscle cells since either ouabain or the incubation in a K+-free solution 
attenuated relaxation to both tamoxifen and SNP. Above-mentioned studies showed the 
positive involvement of endothelium-derived N O in tamoxifen-induced relaxation (Figtree et 
al., 2000; Hutchison et al., 2001) but did not carry on further investigation of the target sites 
for N O . This study has thus provided novel evidence for the role of Na+-K+-ATPase in 
endothelium (NO)-dependent relaxation to tamoxifen in porcine coronary arteries. 
The present study also examined the acute effect of estradiol in the same preparations. 
It was found that unlike tamoxifen, estradiol induced endothelium-independent relaxation, 
which is partially sensitive to inhibition by ICI 182,780, and that estradiol concentration-
dependently relaxed 60 mmol/L KCl-contracted rings, which was slightly reduced by ICI 
182,780. There are apparent differences in vascular responses to tamoxifen and estrogen in 
porcine coronary arteries. The former involves endothelial N O and the latter is related to 
vascular smooth muscle cells. Besides, tamoxifen relaxes arteries via a NO-dependent and 
ouabain-sensitive pathway while ouabain had no effect on estradiol-induced relaxation. 
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It has been recently described that endothelium-derived superoxide could inhibit the 
stimulatory effect of N O on vascular Na+-K+-ATPase activity probably by inactivating N O 
(Gupta et al., 2002). Therefore this study cannot exclude a possible acute suppression of the 
production of reactive oxygen species in situ by tamoxifen in intact coronary arteries and this 
possibility deserves further examination. 
Taken together, the present study has provided novel evidence for the involvement of 
ouabain- and BaCli-sensitive mechanisms in relaxation to tamoxifen in isolated porcine left 
circumflex coronary arteries. Tamoxifen has been shown to acutely relax several systemic 
blood vessels (Figtree et al., 2000; Wickman & Vollrath, 2000; Hutchison et aL, 2001; Park et 
al., 2003) and chronic tamoxifen treatment reduced cerebrovascular tone (Tsang et al., 2004a) 
and modulated m R N A expression of voltage-sensitive Ca^^ channels and K+ channels in 
ovariectomized female rats (Tsang et al., 2004c). These basic research findings together with 
results from this study highlight the importance of the beneficial effects of tamoxifen on the 
coronary and cerebrovascular reactivity, which could, at least in part, protect against coronary 
artery disease as reported in both women (McDonald & Stewart, 1991; McDonald et al., 1995) 
and men (Clarke et al., 2001). 
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CHAPTER IV 
Endothelium-Independent Relaxation to Raloxifene in Porcine 
Coronary Arteries 
4.1. Abstract 
As a second-generation selective estrogen receptor modulator (SERM), raloxifene, 
possesses estrogen-like cardiovascular protective effects and is considered to be a potential 
alternative to hormone replacement therapy (HRT) in postmenopausal women. Although the 
vascular action of raloxifene has been examined in several vascular beds, the underlying 
mechanisms are still incompletely understood. The role of endothelium in raloxifene-induced 
vascular responses was controversial. The present study aimed at examining the endothelium-
independent vascular effects of raloxifene in isolated porcine left circumflex coronary arteries. 
Changes in isometric force were measured by force-displacement transducers and whole-cell 
K+ currents were recorded using patch-clamp technique. Treatment with raloxifene (1-10 
}imol/L) reduced the contractile responses to 9,11 -dideoxy-11 a,9a-epoxy-
methanoprostaglandin F2a (U46619), serotonin (5-HT), endothelin-1 (ET-1) in normal Krebs 
solution and to CaCli in a Ca^.-free, high K+-containing solution. In ET-1-precontracted rings, 
raloxifene (0.3 to 50 jimol/L) induced relaxation in arterial rings and the relaxation was 
identical in rings with and without endothelium. The raloxifene-induced relaxation was 
reduced by putative K+ channel blockers, iberiotoxin (IBX) or tetraethyl ammonium chloride 
(TEA+) in rings with and without endothelium, or by elevated extracellular potassium ions (30 
mmol/L K+ and 60 mmol/L K+). ICI 182,780 did not affect raloxifene-induced relaxation, but 
inhibited estrogen-induced relaxation. Raloxifene (10 |imol/L) enhanced outward large-
conductance Ca2+-activated K+ (BKca) currents, which were sensitive to inhibition by 100 
nmol/L IBX. In summary, the results of the present investigation show that raloxifene acutely 
relaxes porcine coronary arteries largely via an endothelium-independent mechanism without 
involving ICI 182,780-sensitive estrogen receptor. It appears that raloxifene mainly acts on 
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vascular smooth muscle cells to induce vasorelaxation by inhibition of C a� . channels and 
activation of BKca channels. The former is likely to be more important than the latter. 
4.2. Introduction 
Despite a significant reduction in the risk of heart attacks in w o m e n receiving hormone 
replacement therapy (HRT) as reported in early observational studies (Sullivan et al., 1990), 
two recent large-scale clinical trials of H R T for either primary or secondary prevention of 
heart disease failed to demonstrate an overall therapeutic benefit. Instead, H R T caused an 
increase in the incidence of heart attack and stroke (Hulley et al., 1998; Rossouw et al., 2002). 
Therefore, conventional H R T is no longer recommended for postmenopausal women 
(Rossouw et al., 2002; Riggs et ai, 2003). 
The development of selective estrogen receptor modulators (SERMs) marks a new 
phase in the postmenopausal medication, and represents a major step forward in finding 
alternative therapies to H R T . Due to the tissue specificity and mixed estrogen-
agonistic/antagonistic properties, SERMs, such as raloxifene, manifest estrogenic activity in 
bone, cardiovascular system, and central nervous system, while avoiding or opposing harmful 
effects of H R T in breast and uterus. 
Preclinical trials showed that raloxifene reduced aortic accumulation of cholesterol in 
cholesterol-fed rabbits (Bjamason et al., 1997), suggesting a potential usefulness against the 
development of atherosclerosis. Randomized clinical trials showed that raloxifene and 
estrogen shared similar favorable effects on lipid profiles. Raloxifene decreased total 
cholesterol and low density lipoprotein (LDL) (Delmas et al., 1997; Draper et al., 1996). In 
addition, raloxifene also lowered other cardiovascular risk factors in the plasma, such as 
fibrinogen, plasminogen activator inhibitor-1, and homocysteine (Walsh et al., 1998; 
Mijatovic et al., 1998). Treatment with raloxifene augmented flow-mediated endothelium-
dependent vasodilatation, increased the plasma nitric oxide (NO) and decreased the plasma 
endothelin-1 levels in healthy postmenopausal women (Saitta et aL, 2001). Recently, 
raloxifene has been reported to acutely reduce the contractile responses to agonists such as 
U46619，endothelin-1, and phenylephrine (Tsang et al., 2004b). 
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Animal studies indicate that raloxifene exerts estrogen-like cardio-protective action. 
For example, raloxifene prevents cardiac hypertrophy and dysfunction in pressure-overloaded 
mice (Ogita et al., 2004) and ameliorates ischemia/reperfusion injury to canine hearts (Ogita et 
al., 2002). This cardiac protection is likely to attribute to the improved coronary circulation 
(Zoma et al., 2000). In ovariectomized sheep receiving raloxifene, coronary arteries with 
greater diameters were observed compared with those receiving estrogen or no treatment 
(Gaynor et al., 2000). 
O n the other hand, nongenomic signaling via estrogen receptors accounts for many 
estrogen-mediated vascular actions in vitro. For example, raloxifene-induced endothelium-
dependent relaxation in rabbit coronary arteries was antagonized by ICI 182,780, a classic 
estrogen receptor antagonist (Figtree et al, 1999). Raloxifene-induced activation of 
endothelial N O synthesis was also inhibited by ICI 182,780 (Simoncini et al., 2002). 
Despite the beneficial effects described for raloxifene in the heart and coronary 
circulation, the mechanisms underlying these effects in coronary blood vessels remain poorly 
understood. Thus, the objectives of the present study were to investigate roles of endothelium, 
estrogen receptor, Ca^^ channels, and K+ channels in vasorelaxation to raloxifene in isolated 
porcine left circumflex coronary arteries. 
4.3. Methods and Materials 
4.3.1. Vessel Preparation 
All experiments described in this study were approved by the Animal Experimentation 
Ethics Committee, Chinese University of Hong Kong. This investigation conformed to the 
Guide for the Care and Use of Laboratory Animals published by the U S National Institute of 
Health (NIH Publication No. 85-23, revised 1996). 
Fresh pig hearts were obtained from a local slaughterhouse in Hong Kong. The hearts 
were placed on a dissecting plate filled with ice-cold Krebs solution containing (mmol/L): 119 
NaCl, 4.7 KCl, 2.5 CaCli, 1 MgCL, 25 NaHCO], 1.2 KH2PO4, and 11 D-glucose. After fatty 
connective tissues were trimmed off, each left circumflex coronary artery was cut into several 
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ring segments,〜3 m m in length. Each ring was suspended in an organ bath filled with Krebs 
solution. Bathing solution was continually oxygenated with a gas mixture containing 9 5 % O2 -
5 % CO2 and maintained at 37 (pH:〜7.4). Each ring was stretched to an optimal tension of 
15 m N , which was determined by length-tension relationship and thereafter allowed to 
equilibrate for 〜90 min before the start of the experiment. In some rings, the endothelial layer 
was mechanically removed by gently rubbing the luminal surface with forceps tip and 
functional removal was confirmed by the lack of a relaxant response to 50 nmol/L bradykinin. 
Each experiment was performed on rings isolated from different pig hearts. 
4.3.2. Isometric Force Measurement 
Thirty min after setting up the organ baths, each ring was challenged with 60 mmol/L 
K+ at 30-min intervals until the two consecutive contractions were similar in amplitude (< 
10%). Thereafter, concentration-response curves were studied in rings contracted by U46619 
(0.3 to 300 nmol/L), serotonin (0.03 to 10 jimol/L), endothelin-1 (0.1 to 50 nmol/L) in the 
absence or presence of raloxifene (0.3 to 30 |imol/L, 30-min preincubation). The ability of 
raloxifene to modulate Ca^ "" influx via L-type Ca^^ channels was evaluated by studying the 
concentration-dependent responses to C a C b (0.001 to 5 mmol/L) in the absence or presence of 
raloxifene (1 to 10 ^ imol/L). In this set of experiments, rings were rinsed three times in a Ca^^-
free solution, then incubated in a Ca^^-free, 60 mmol/L K+-containing solution (without or 
with raloxifene, 30-min preincubation) before cumulative addition of CaCl2. 
In the second series of experiments, rings were first contracted by 30 nmol/L U46619 
and subsequently challenged with 50 nmol/L bradykinin to confirm the integrity or removal of 
the endothelium. They were then washed in Krebs solution several times until baseline tone 
was restored and finally allowed to stabilize for 60 min. The roles of endothelium, estrogen 
receptors, and K+ channels were examined in coronary artery relaxant responses to raloxifene 
by using various pharmacological inhibitors. The effect of raloxifene was compared between 
rings with and without endothelium. Rings were exposed for 30 min to each of the following 
inhibitors [1 |imol/L ICI 182,780 (a classical estrogen receptor inhibitor), 100 nmol/L IBX (a 
BKca channel blocker) or 1 mmol/L TEA+ (a non-selective K+ channel blocker)] before the 
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addition of endothelin-1 (10 nmol/L). Once a steady contraction was obtained, raloxifene was 
applied cumulatively to bathing solution. Only one concentration-response curve to raloxifene 
was constructed from each ring since the effect of raloxifene cannot be readily washed out. 
The relaxing effect of raloxifene was also studied on 30 mmol/L K+- and 60 mmol/L K+-
constricted rings in normal Ca^^-containing Krebs solution. 
4.3.3. Electrophysiological Study of BKca Current 
4.3.3.l.Enzymatic Dissociation of Coronary Artery Smooth Muscle Cells 
Strips of left circumflex coronary artery (1mm x 1 m m ) were placed in an Eppendorf 
tube (1.5 ml) containing a low [Ca�.]。dissociation medium of the following composition (in 
mmol/L): NaCl 110, KCl 5, NaHsPO* 0.5, KH2PO4 0.5, N a H C O s 10, 4-(2-
hydroxyethyl)piperazine-1 -ethanesulfonic acid (HEPES) 10, Phenol Red 0.015, taurine 10, 
creatine 5, N a pyruvate 5, glucose 11, CaCli 0.16, M g C b 2, 1-ascorbic acid 0.3, and 
ethylenediaminetetraacetic acid (EDTA) 0.5 (pH 7.0 with NaOH). The arterial strip was 
incubated for 45-60 min at 37 °C in the above solution (vol. 1 ml) with the supplement of 6 m g 
dithiothreitol (Sigma-Aldrich, USA), 2 m g papain (Fluka, Switzerland), 7.5 m g collagenase 
(Type 2, Worthington Biochemicals Inc., USA), and 2 m g bovine serum albumin (essential 
fatty acid-free) (Sigma-Aldrich, USA). After incubation, the digested tissue was transferred to 
an enzyme-free dissociation solution, and gently triturated with a fire-polished Pasteur pipette 
to release single smooth muscle cells. Electrophysiological recordings were carried out only 
on cells that exhibited morphological features of vascular smooth muscle cells (an elongated, 
spindle shape,〜100 in length) when observed under the microscope (Au et aL, 2003). 
Moreover, single smooth muscle cell showed reversible contractions in response to high 
[K+]out (50 mmol/L). 
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4.3.3.2.Electrophysiological Recording 
A drop of cell suspension was placed in a glass-bottom recording chamber (vol.〜0.5 
ml), mounted on the stage of an inverted microscope (Nikon Diaphot 200, Japan) equipped 
with a Hoffman Modulation Contrast condenser, containing a physiological salt solution of the 
following composition (mmol/L): NaCl 132, KCI 4.8, H E P E S 10, MgCl] 2, glucose 5，and 
CaCl2 1 (pH 7.4 with NaOH). Cells that were relaxed and had a clear edge observed under the 
microscope were used in this study. Voltage-clamp and voltage-pulse generation were 
controlled with an Axopatch 200A patch-clamp amplifier (Axon Instruments, Forster City, 
CA, USA), and data were acquired and analysed using p C L A M P software (Axon Instruments, 
Forster City, CA, USA). 
In all experiments, the BKca current amplitude was recorded at room temperature (-22 
using the single micropipette "giga-seal" whole-cell, perforated-patch techniques. Families 
of macroscopic BKca currents were generated by stepwise 20 m V depolarising pulses (pulse 
duration: 500 ms, holding potential = -70 m V ) from —70 m V to 90 m V , stimulated at 0.166 
Hz. The external recording solution contained (mmol/L): NaCl 140, KCI 5, CaCli 1，MgCli 2, 
H E P E S 10, glucose 5 (pH 7.4 with NaOH). The tip of the pipette was dipped (for 〜15 s) into 
internal solution containing (mmol/L): K2SO4 60，KCI 30，MgCb 5, C a C h 5, H E P E S 5 and 
M g S 0 4 40 (pH 7.2 with K O H ) (Ruehlmann et al., 1998; White et al., 2002). The remainder of 
the patch pipette was back-filled with the same solution to which amphotericin B (6 mg/ml) 
was added. Series resistance was compensated to provide the fastest decay of the capacitative 
current with no sign of ringing. Pipettes were fabricated from haematocrit glass capillaries 
(Accu-Fill 90 Micropet, Clay Adams, U.S.A.) and pulled on a two-stage vertical pipette puller 
(PP-83; Narishige Scientific Instruments, Japan). The pipette tip was position near the nuclear 
region of the coronary artery smooth muscle cell (dimension 〜10 using an oil-based 
hydraulic micro-manipulator (Narishige Scientific Instruments, Japan). Current amplitude 
recorded was filtered at 5 kHz and sampled at 3-10 kHz. Cell membrane capacitance was 
estimated, as previously described (Matsuda et al., 1990, A u et al., 2003), and it was 19.2 土 
2.3 pF (n 二 20). Current amplitude, expressed as current density (in pA/pF), was recorded 
before (control), during (treating) and after (washing) the administration of a particular drug. 
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Only one concentration of an individual drug was tested in each cell. Cells with visible change 
in leakage currents during the course of study were discarded and excluded from analysis. 
External solution was delivered, through gravity, and controlled by solenoid valves coupled to 
a 4-channel valve driver (General Valve, USA). Solution change (〜5 ml, which is 10 times the 
volume of the recording chamber) could be completed in 15-20 s. 
4.3.4. Chemicals 
Bradykinin, U46619, TEA+ and IBX (Sigma), ICI 182,780 and ET-1 (Tocris, UK), 5-
H T (Serotonin) (RBI), Raloxifene hydrochloride (Eli Lilly & Co.) All chemicals for preparing 
physiological salt solution, dissociation medium, external recording solution and internal 
pipette solution were purchased from Sigma-Aldrich Chemicals Co. (St. Louis, M O , U.S.A.). 
U46619, ICI 182,780 and raloxifene were dissolved in dimethyl sulfoxide ( D M S O ) and stock 
solution was diluted to desired concentration before the experiments. Other chemicals were 
prepared in nanopure water and further dilution was made in Krebs solution. Treatment with 
D M S O (at 0.1% v/v) alone did not modify contraction or relaxation in porcine coronary 
arteries. 
4.3.5. Data Analysis 
The contractile force was presented as percentage of the mean value of two 
consecutive contractions in response to 60 mmol/L KCl. Results are mean 土 S.E.Ms of n 
experiments and n refers to the number of artery rings studied from different pigs. Several 
rings prepared from the same artery were examined in parallel. The relaxant responses were 
calculated as percentage reduction of the constrictor-induced tone in each ring. Curves were 
analyzed by non-linear curve fitting using Graphpad software (Version 3.0) and statistical 
differences between concentration-response curves were analyzed by two-way A N O V A 
followed by Bonferroni post-tests. The negative logarithm of the dilator (or constrictor) 
concentration that produced half of the maximal relaxation {^Di) or maximal contraction 
(pECso) was calculated. For statistical analysis, one-way analysis of variance followed by 
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Newman-Keuls test was used when more than two groups were compared. P values of less 
than 0.05 were taken as statistically significant. 
4.4. Results 
4.4.1. Effect of Raloxifene on Agonist-Induced Contractions 
The representative traces in Figure 1 show the inhibitory effects of 10 |imol/L 
raloxifene on contractile responses to U46619 (Fig. 4.1a), serotonin (Fig. 4.1b), endothelin-1 
(Fig. 4.1c), and CaC^ (Fig 4.Id) in arterial rings with endothelium. Effect of raloxifene to 
U46619, serotonin, endothelin-1 and CaCh -induced contractions (expressed as percentage of 
60 mmol/L K+-induced tone) with pECso of 8.87 士 0.25 (n=6), 6.618 士 0.38 (n=6), 8.64 士 0.02 
(n=6), and 4.09 士 0.06 (n=6) respectively is shown in Fig. 4.2. Raloxifene at concentrations 
greater than 0.1 jimol/L inhibited agonist-evoked contraction with suppression of the 
magnitude of maximal contraction (Fig. 4.3a, 4.3b, 4.3c & 4.3d) and slopes of concentration-
response curves for all four constrictive agonists (Fig. 4.2). Fig. 4.3 summarizes the values for 
maximal contraction induced by each constrictor in the absence and presence of raloxifene. 
The order of effectiveness for raloxifene (10 |imol/L)-induced inhibition of contraction was 
CaCl2 > U46619 > serotonin > endothelin-1 (Fig. 4.3). 
4.4.2. Role of the Endothelium 
Raloxifene induced concentration-dependent relaxations in rings with or without 
endothelium contracted by endothelin-1. There was no difference in the relaxation under either 
condition (pDi： 4.72 士 0.31 with endothelium and 4.28 士 0.86 without endothelium, n二8-12; 
Fig. 4.4a). 
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4.4.3. Effect of Elevated Extracellular K+ Concentrations 
Both 30 mmol/L and 60 mmol/L extracellular KCl reduced raloxifene-induced 
relaxation as compared with the relaxation rings contracted by endothelin-1 in normal KCl-
containing solution (Fig. 4.4b). 
4.4.4. Effect of Putative K+ Channel Blockers 
TEA+ (1 mmol/L) and IBX (100 nmol/L) reduced raloxifene-induced relaxation to a 
similar degree in rings with endothelium (Fig. 4.4c) or without endothelium (Fig. 4.4d). 
4.4.5. Effect of Estrogen Receptor Antagonist 
Treatment with ICI 182,780 (1 jimol/L) failed to affect raloxifene-induced relaxation 
in rings with endothelium (pZ)2： 4.66 士 0.35, n=5 in control and 4.95 士 0.21, n=5 in ICI 
182,780; P > 0.05; Fig. 4.5b); whereas treatment with ICI 182,780 (1 }imol/L) reduced 
estrogen-induced relaxation in rings with endothelium (P < 0.001; Fig. 4.5a). 
4.4.6. Effects of Raloxifene on BKca Current 
Raloxifene (10 \imo\/L) stimulated increases in outward K+ currents probably through 
BKca channels (Fig. 4.6 & 4.7) since this current was markedly inhibited (-85% inhibition) by 
IBX (100 nmol/L) (n = 4) (BKca amplitude measured at +90 m V : 71 ± 5 pA/pF in control and 
11 土 4 pA/pF in IBX, P < 0.001)，indicating that the current recorded in this study was 
mediated by BKca channels (Fig. 4.8). 
Stimulatory effect of raloxifene on BKca currents was concentration-dependent 
[increase in the current: 10 ± 2 pA/pF in 1 ^imol/L, n二6, (4 out 6 cells showed complete 
washout of drug); 708 士 68 pA/pF in 10 jamol/L, n=6, (1 out 6 cells showed complete washout 
of drug); and 1416 土 99 pA/pF in 30 ^ imol/L, n=6, (none of 6 cells showed washout of drug): 
(Fig. 4.9). 
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Fig. 4.1. The representative records showed inhibitory effects of raloxifene (10 |imol/L, 30-
min incubation) on contractions to cumulative addition of U46619 (a), serotonin (5-HT, b), 
endothelin-1 (ET-1, c), and CaCl! (d) in isolated porcine coronary arteries. These experiments 
were performed on rings with endothelium. Rings were contracted twice by high KCl (60 
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Fig. 4.2. (a) U46619-induced contractions in the absence (〇，n=6) or presence (參,n=6-7) of 
raloxifene (1 to 30 |imol/L). (b) Serotonin (5-HT)-induced contraction in the absence (〇，n=6) 
and presence (•，n=6) of raloxifene (0.3 to 10 jimol/L). (c) Endothelin-1-induced contractions 
in the absence (〇，n=6) and presence (•，n二6) of raloxifene (1 to 10 jimol/L). (d) CaCb-
induced contraction in a Ca^^-free, 60 mmol/L KCl-containing solution in the absence (〇， 
n=5) and presence (•, n=6) of raloxifene (1 to 10 fimol/L). All experiments were carried out 
on rings with endothelium. Results are mean 士 S.E.Ms of n experiments. 
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Fig. 4.3., Raloxifene reduced the sensitivity and potency of agonist-induced contraction. 
Based on the concentration-response curves shown in Fig. 4.2, the E^ax values for evoked 
contraction were calculated for U46619 (a), 5-HT (b) endothelin-1 (c), and CaCli (d) in 
control and in the presence of different concentrations of raloxifene. Results are mean 士 
S.E.Ms of n experiments. Significant difference between control and raloxifene-treated groups 
is indicated by (* P < 0.05, * * P < 0.01 and *** P < 0.001). 
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Fig. 4.4. (a) Raloxifene-induced relaxation in rings contracted by endothelin-1 (〇 with 
endothelium and • without endothelium; n=8-13). (b) Raloxifene-induced relaxation in rings 
contracted by 30 mmol/L and 60 mmol/L KCl. Inhibitory effects of TEA+ and IBX on 
raloxifene-induced relaxation in rings with (c) and without endothelium (d). Rings were 
exposed to inhibitor 30 min prior to the addition of endothelin-1. Statistical differences are 
indicated by “ between control group and TEA+ group, and 办 between control group and IBX 
group (* P < 0.05，** P < 0.01，*** P < 0.001). Results are mean 士 S.E.Ms of n experiments. 
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Fig. 4.5. Raloxifene (a)- or 17 /5 -estradiol (b)-induced relaxation in rings contracted by 
endothelin-1 in the absence (〇)and presence (•) of 1 |imol/L ICI 182,780 (n=6-7). Rings with 
endothelium were exposed to ICI 182,780 for 30 min before the addition of endothelin-1. (*** 
P < 0.001) Results are mean 士 S.E.Ms of n experiments. 
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Fig. 4.6. Stimulatory effect of raloxifene (10 ！imol/L) on whole-cell large-conductance Ca^^-
activated K+ channel (BKca) current recorded in a single coronary artery smooth muscle cell. 
Series of macroscopic BKca currents were triggered by stepwise 20 mV-increment in 
depolarizing pulses (pulse duration: 500 ms, holding potential = -70 m V ) from -70 m V to 90 
m V , stimulated at 0.166 Hz). 
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Fig. 4.7. Current-voltage relationship of BKca currents measured on the peak sustained current 
in control (〇)，during the presence of raloxifene (10 ^imol/L) (•) and after washout of 
raloxifene (A). Results are mean 士 S.E.Ms of 4 separate recordings. 
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Fig. 4.8. BKca current records showing the inhibitory effect of 100 nmol/L iberiotoxin (IBX) 
on raloxifene (10 |amol/L)-stimulated increase in the BKca current. 
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Fig. 4.9. Concentration-dependent stimulatory effect of raloxifene on BKca currents after 
subtraction from the control current in the absence of raloxifene. 
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4.5. Discussion 
The present study examined the vascular effects of raloxifene on isolated porcine 
coronary arteries with or without a functional endothelium. The main results of this study 
include: (i) raloxifene reduced vascular contractions to both receptor-dependent and -
independent constrictors; (ii) raloxifene reduced CaCh-mediated contraction probably via 
inhibition of Ca^^ influx through voltage-sensitive Ca^^ channels; (iii) raloxifene-induced 
relaxation was attenuated by K+ channel blockers and raloxifene-stimulated increases in 
outward K+ currents through BKca channels, suggesting activation of K+ channels may be 
involved; and (iv) raloxifene-induced relaxation was independent of the presence of 
endothelium and was unrelated to ICI 182,780-sensitive estrogen receptor in porcine coronary 
arteries. 
Voltage-sensitive Ca^^ channels are activated by membrane depolarization in vascular 
smooth muscle cells when the extracellular K+ concentration is elevated. Raloxifene markedly 
reduced the contractile responses to CaCli-induced contractions in a Ca2+-free, high K+ 
solution. Similar observations were also made in rabbit coronary arteries (Figtree et al., 1999), 
rat pulmonary arteries and rat renal arteries (Chan et aL, 2005; Leung et al., 2005). The direct 
evidence was provided for the antagonistic effect of raloxifene on L-type voltage-sensitive 
Ca2+ currents in vascular smooth muscle isolated from rat cerebral arteries (Tsang et aL, 
2004b), even though it remains unclear how raloxifene inhibits Ca^^ channels on vascular 
smooth muscle. 
Raloxifene reduced contractile responses to three receptor-dependent constrictors, 
U46619, serotonin, and endothelin-1, in a concentration-dependent manner, but with varied 
potency. Raloxifene at 1 fimol/L reduced serotonin-induced maximal contraction by -72%, 
but it had lower potency in rings contracted with endothelin-1 (〜23o/o) or U46619 (〜14o/o). 
Serotonin serves as a novel marker for atherosclerotic vascular disease (Hirowatari et aL, 
2004) and the increased plasma concentration of endothelin-1 serves as another marker of 
atherosclerosis and hypertension (Glowinska et al., 2004). Besides, the increased levels of 
thromboxane A2 (U46619 is a thromboxane A2 analogue) reflected endothelial dysfunction 
(Drexler & Homig, 1999). The anti-contractile effects of raloxifene against U46619, serotonin 
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and, endothelin-1 suggest that raloxifene may be potentially useful in the prevention and 
treatment of atherosclerosis-associated coronary artery disease. 
Raloxifene-induced relaxation was similar in rings with or without endothelium. These 
results suggest that raloxifene exerts an endothelium-independent action. ICI 182,780 (a 
selective estrogen receptor antagonist) did not affect raloxifene-induced relaxation, whereas it 
reduced the 17P-estradiol-induced relaxation. This estrogen receptor antagonist also failed to 
antagonize raloxifene-mediated relaxation in porcine femoral veins (Bracamonte et al., 2002), 
in rat cerebral arteries (Tsang et al., 2004b), and in rat pulmonary arteries (Chan et al., 2005). 
In contrast, ICI 182,780 inhibited endothelium-dependent relaxation to raloxifene in rabbit 
coronary arteries without any effect on rings without endothelium (Figtree et al., 1999)，and it 
blocked raloxifene-induced N O production in human endothelial cells (Simoncini et al,, 
2002). It seems that raloxifene-induced (non-genomic) effects on the endothelium are more 
likely mediated through ICI 182,780-sensitive estrogen receptor, whereas the acute effect on 
vascular smooth muscle cells is probably independent of the classical estrogen receptor. 
Raloxifene-induced relaxation was reduced in rings contracted by high KCl solutions, 
indicating indirectly that K+ channels may involve in the relaxation. Estrogen relaxes porcine 
coronary arteries by opening BKca channels (White et al,, 1995) in the absence of functional 
endothelium. Raloxifene-induced endothelium-independent relaxation is likely to be mediated, 
at least in part, via opening BKca channels since two putative BKca channel blockers, IBX and 
TEA+ attenuated raloxifene-induced relaxation to a similar extent in rings with or without 
endothelium. Further supporting evidence came from the electrophysiological study. 
Raloxifene at concentrations that relaxed porcine coronary arteries increased the outward K+ 
currents through IBX-sensitive BKca channels, recorded on single smooth muscle cells 
isolated enzymatically from porcine coronary arteries. 
In summary, the results of the present study indicate complex mechanisms that account 
for in vitro relaxation to raloxifene in isolated porcine left circumflex coronary arteries. 
Raloxifene-induced endothelium-independent relaxation was mediated via two main 
mechanisms: (i) inhibition of Ca"^ influx via voltage-sensitive Ca"^ channels as shown in other 
vascular beds and (ii) activation of Ca"'^ -activated K+ channels in vascular smooth muscle, 
which indirectly reduces Ca^^ influx through membrane hyperpolarization. Neither 
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endothelium nor ICI 182,780-sensitive estrogen receptor were involved in the acute 
vasorelaxation to raloxifene. The actions of raloxifene demonstrated in this study are acute and 
non-genomic. In the present study, the threshold concentration shown to be effective in 
relaxing coronary arteries is between 0.3-1 jj,mol/L for raloxifene. However, the in vitro study 
did not include any effects of other circulating hormones and dilating factors, which may be 
enhanced by raloxifene in vivo. There was difficulty in knowing the gender of pigs from which 
the hearts were obtained. Therefore, the possible gender difference in the vascular response to 
raloxifene in coronary circulation is unknown. Notwithstanding, the vascular effects of 
raloxifene described in this study enhance the perspectives of raloxifene and other S E R M s as 
novel drugs in the treatment of coronary artery disease. 
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CHAPTER V 
Therapeutic Concentrations of Raloxifene Augment Bradykinin 
Mediated Nitric Oxide-Dependent Relaxation in Porcine Coronary 
Arteries 
5.1. Abstract 
Raloxifene may confer beneficial effects of estrogen in the cardiovascular system by 
improving endothelial function. The present study was aimed at testing the hypothesis that 
therapeutic concentrations of raloxifene could augment endothelium-dependent relaxation in 
porcine coronary arteries. Changes in isometric force were measured by force-displacement 
transducers, and endothelial intracellular Ca^ "^  concentrations in endothelium-intact 
arteries was detected by a Ca^^ fluorescence imaging technique. In 9,11-dideoxy-l la,9a-
epoxy-methanoprostaglandin Fia (U46619)-precontracted rings, treatment with raloxifene (1-3 
nmol/L) potentiated bradykinin- or substance P-, but not A23187-induced relaxation and this 
effect was antagonized by ICI 182,780. The enhanced relaxation was abolished in rings treated 
by inhibitors of nitric oxide/cyclic GMP-dependent dilation, N*^-nitro-L-arginine methyl ester 
(L-NAME) plus lH-[l,2,4]oxadizolo[4,3-a]quinoxalin-l-one (ODQ). In contrast, the effect of 
raloxifene was unaffected after inhibition of endothelium-derived hyperpolarizing factors by 
charybdotoxin (CTX) plus apamin. Raloxifene (3 nmol/L) did not influence endothelium-
independent relaxation to sodium nitroprusside, a nitric oxide (NO) donor. Estrogen (3-10 
nmol/L) also potentiated the bradykinin-induced relaxation in an ICI 182,780-sensitive 
manner. Treatment with raloxifene (3 nmol/L) did not affect bradykinin-stimulated rise in 
endothelial in situ in rings with endothelium. In summary, therapeutic concentrations 
of raloxifene augmented bradykinin-induced coronary artery relaxation via an ICI 182,780-
sensitive estrogen-receptor-mediated NO-dependent mechanism which may not involve 
changes in endothelial [Ca^ j^j. 一 
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5.2. Introduction 
The risk of cardiovascular disease associated with endothelial dysfunction rises sharply 
in w o m e n after menopause partly due to estrogen deficiency. Previous observational studies 
reported a significant reduction in the incidence of heart attacks in w o m e n who took hormone 
replacement therapy (HRT) (Sullivan et al, 1990). Recent clinical trials of H R T for primary 
or secondary prevention of heart disease have, however, demonstrated no overall therapeutic 
benefit in menopausal women; instead, H R T users had greater risks of suffering from heart 
disease and stroke (Hulley et al., 1998; Rossouw et al., 2002). 
The discovery and development of selective estrogen receptor modulators (SERMs) 
represent a significant advance towards finding alternative therapies to HRT. Due to the 
tissue-specific and mixed estrogen-agonist/antagonist properties, SERMs, such as raloxifene, 
manifest estrogenic activity in bone, cardiovascular system, and central nervous system while 
avoiding or opposing harmful effects of H R T in breast and uterus. Animal studies indicate that 
raloxifene exerts estrogen-like cardioprotective actions. For example, raloxifene prevents 
cardiac hypertrophy and dysfunction in pressure-overloaded mice (Ogita et al., 2004) and 
ameliorates ischemia/reperflision injury to canine hearts (Ogita et al., 2002). This cardiac 
protection is likely to result from improved coronary circulation (Zoma et al,, 2000). Indeed, 
coronary arteries have greater diameters in ovariectomized sheep receiving raloxifene 
compared with those receiving estrogen or no treatment (Gaynor et al., 2000). O n the other 
hand, raloxifene acutely causes both endothelium-dependent and -independent rabbit coronary 
artery relaxation; the former but not the latter is antagonized by ICI 182,780, a classic estrogen 
receptor antagonist (Figtree et al., 1999). However, the rapid relaxing effect usually occurs in 
response to pharmacological (micromolar) concentrations of raloxifene (Figtree et al” 1999; 
Tsang et al., 2004b). Long-term oral administration of raloxifene (60 m g per day) to women 
results in the detection of a mean maximum plasma concentration of 1.36 f^ g/L, equivalent to 
2.67 nmol/L raloxifene (Snyder et al., 2000; Morello et al., 2003), a concentration that does 
not cause noticeable relaxation in isolated blood vessels studied so far. This would raise a 
likelihood that plasma raloxifene concentrations after therapeutic dosing may synergize with 
other circulating vasodilators as an important mechanism by which raloxifene improves 
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endothelial function. Therefore, w e tested whether raloxifene could synergize the effect of 
other endothelium-dependent dilators in freshly isolated porcine coronary arteries. 
5.3. Methods and Materials 
5.3.1. Vessel Preparation 
All experiments described below were approved by the Animal Research Ethics 
Committee, Chinese University of Hong Kong. This investigation conformed to the Guide for 
the Care and Use of Laboratory Animals published by the U S National Institute of Health 
(NIH Publication No. 85-23, revised 1996). 
Fresh pig hearts were obtained from a local slaughterhouse in Hong Kong. The hearts 
were placed on a dissecting plate filled with ice-cold Krebs solution containing (mmol/1): 
NaCl 119, KC14.7, CaCli 2.5, M g C h l,NaHC03 25, KH2PO4 1.2, and D-glucose 11. After fatty 
connective tissues were trimmed off, each left circumflex coronary artery was cut into several 
ring segments,〜3 m m in length. Each ring was mounted in an organ bath filled with Krebs 
solution that was continually oxygenated with 9 5 % O2 - 5 % CO2 and maintained at 37 (pH: 
7.3 - 7.5). Each ring was stretched to an optimal tension of 15 m N , and thereafter allowed to 
equilibrate for 〜90-min before the start of each experiment. In some rings, the endothelial 
layer was mechanically removed by gently rubbing the luminal surface with forceps tip and 
functional removal was confirmed by lack of a relaxant response to Bradykinin (50 nmol/L). 
Each experiment was performed on rings isolated from different pig hearts. 
5.3.2. Isometric Force Measurement 
Thirty min after setting up in organ baths, each ring was challenged twice with 60 
mmol/L KCl followed by U46619 (30 nmol/L). After adding bradykinin to substantiate the 
presence of a functional endothelium, rings were rinsed in pre-warmed Krebs solution several 
times until baseline tone was reestablished. T w o consecutive concentration-response curves 
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(CRC) to bradykinin (1-50 nmol/L) were studied in control and in the presence of raloxifene 
(1-3 nmol/L, 30-min incubation) before repeating the second C R C . To test the role of N O or 
endothelium-derived hyperpolarizing factor (EDHF), rings were exposed for 30 min to 
respective inhibitors before the addition of raloxifene. These inhibitors included N -nitro-L-
arginine methyl ester (100 |amol/L, L - N A M E ) plus 1 H-[l,2,4]oxadizolo[4,3-a]quinoxalin-1 -
one (3 |imol/L, O D Q ) (a recipe to block NO/cyclic GMP-mediated relaxation) or C T X (50 
nmol/L) plus apamin (50 nmol/L) (a recipe to inhibit EDHF-mediated relaxation). ICI 182,780 
(1 fimol/L) was examined for its effect on vascular responses to raloxifene. Bradykinin-
induced relaxation was eliminated after combined treatment with L - N A M E and O D Q , C T X 
and apamin; but it was unaffected by indomethacin (1 |imol/L, an inhibitor of prostacyclin 
synthesis). Finally, the effect of raloxifene (3 nmol/L) was studied on relaxation to sodium 
nitroprusside (an exogenous N O donor) in rings without endothelium. 
For comparison, the low concentrations of estrogen (3-10 nmol/L) were also examined 
for its interaction with bradykinin in porcine coronary arteries. 
5.3.3. In situ Endothelial Imaging 
Porcine coronary artery rings were fluorescently labeled for 1 hr at 22 °C by incubation 
with a loading solution containing 10 |Limol/L Fura-2 A M , 0.025% pluronic F-127 and 1 
mmol/L probenacid added to prevent Fura 2 from leaking into incubation medium. Thereafter, 
the extracellular Fura-2 A M was washed out. The vessel rings were perfused for 30 min by 
Krebs solution (37 °C ) at 2 ml/min to allow intracellular cleavage of Fura-2 A M into active 
Fura-2 by esterases. 
The [Ca2+]i imaging setup was modified as described before by Huang et al (Huang et 
al., 2000). In brief, after Fura-2 loading, rings were longitudinally cut open and pinned down 
onto a block of silicone elastomer, which was affixed to a base plate of a custom-made flow 
chamber. The base plate was then covered with a gasket and cover glass (24 X 32 m m ) and 
affixed by screws. There was a 1-mm gap between the vessel luminal surface and cover glass 
for flow passage. After mounting, the flow chamber was placed on an inverted microscope and 
perfused with Krebs solution (37 °C) at 2 ml/min. The specimen was illuminated on the stage 
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of the I X 70 Olympus microscope, fitted with a 20X Olympus water immersion objective by 
using a Polychrome IV light source. Fura-2 loaded vascular tissues were sequentially excited 
at 340 and 380 run, and images of the respective 510-nm emissions were collected in 1 sec 
intervals using MetaFluor v4.6 software (Universal Imaging Corp., USA). The emitted light 
was transmitted to a collecting device and then to a cooled charge coupled device (CCD) 
camera. Illumination through the Polychrome IV light source and acquisition by the C C D 
camera were controlled by MetaFluor software. Video frames containing images of cell 
fluorescence were digitized at a resolution of 512 horizontal x 480 vertical pixels. Imaging 
analysis was also performed with a MetaFluor imaging system. Following background 
subtraction, the fluorescence ratio (F340/F380) was obtained by dividing, pixel by pixel, the 
340 n m image by the 380 n m image. Changes in this ratio reflected changes in to 
eliminate potential artifacts caused by variations in cell thickness, intracellular dye distribution 
or photobleaching. Each vascular tissue was challenged first with substance P (0.1 ^imol/L) 
and then bradykinin (0.8 jamol/L) in the absence and presence of 3 nmol/L raloxifene after 
washout of the first response. The vascular tissue was exposed to raloxifene for 30 min prior 
to bradykinin application. L - N A M E (100 |j.mol/L) was continuously present in order to 
2+ . 
minimize possible inhibitory effects of endogenous N O on Ca influx in the endothelium 
(Yao et al., 2003). 
5.3.4. Free Radical Scavenging Assay 
Possible free radical scavenging effects of raloxifene and estrogen were examined as 
previously described (Blois, 1958). a-Tocopherol (vitamin E) was used as a reference 
antioxidant. In brief, 0.5 m L of methanol containing different concentrations (0.1-10 |imol/L) 
of raloxifene or estrogen was mixed in a test tube with 2.5 m L of methanol containing 75 
|jmol/L 2,2-diphenyl-1 -picrylhydrazyl (DPPH). D P P H is a stable free radical with a deep 
purple color in ethanotic solution and a typical absorbance at 517 nm, but becomes pale yellow 
when trapped by an antioxidant. The reaction mixture was kept in dark at room temperature 
for 90 min and the absorbance at 517 n m was thereafter measured. The free radical scavenging 
activity was approximated using the following equation: 
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D P P H scavenging activity (%) = x 100 
where A^ is the absorbance of the incubation D P P H solution without raloxifene, is 
the absorbance of the incubation mixture containing D P P H and raloxifene, and A^ is the 
absorbance of the blank solution (methanol) with D P P H . 
5.3.5. Chemicals 
Bradykinin, U46619, L - N A M E , O D Q , CTX, apamin, indomethacin, and sodium 
nitropmsside, and substance P were purchased from Sigma, and ICI 182,780 was purchased 
from Tocris, and raloxifene hydrochloride was purchased from Eli Lilly & Co. U46619, ICI 
182,780, O D Q and raloxifene were dissolved in dimethyl sulfoxide (DMSO), and stock 
solution was diluted to desired concentration before the experiments. Other chemicals were 
prepared in nanopure water, and further dilution was made in Krebs solution. These agents did 
not affect baseline tone. Treatment with vehicle (dimethyl sulfoxide, D M S O at 0.1% v/v) 
alone had no significant effect on the relaxation response to bradykinin. 
5.3.6. Data Analysis 
Data are mean 士 S.E.Ms and n refers to the number of pigs studied. Several rings 
prepared from the same artery were examined in parallel, and two consecutive cumulative 
concentration-response curves (CRC) were established in each ring. In order to demonstrate 
the contribution of endothelial factors to raloxifene-induced effect, the second C R C (after 
inhibition of N O or E D H F ) in the absence and presence of raloxifene was subtracted from the 
first C R C (control) in each ring. The relaxant response to bradykinin was calculated as 
percentage reduction of the initial tone in each ring precontracted by U46619. Curves were 
analyzed by non-linear curve fitting using Graphpad software (Version 3.0) and statistical 
difference between curves was analyzed by two-way A N O V A followed by Bonferroni post-
tests. The negative logarithm of the dilator concentration that produced half (pZ)2) of the 
maximal relaxation was approximated. In Ca^^ fluorescence measurement, the area under each 
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curve was calculated to represent an integrated measure of changes in endothelial [Ca^ J^i 
(Graphpad Prism). P values less than 0.05 was regarded as statistically significant. 
5.4. Results 
5.4.1. Relaxation to Bradykinin 
Bradykinin induced concentration-dependent relaxation in porcine left circumflex 
coronary arteries and this relaxation depended on the presence of intact endothelial layer. The 
bradykinin-induced relaxation was reduced by treatment with either 100 |amol/L L - N A M E (an 
inhibitor of N O S ) or 3 fimol/L O D Q (an inhibitor of soluble guanylate cyclase) (Fig. 5.1a). 
Treatment with C T X plus apamin, each at 50 nmol/L, inhibited the relaxation to a greater 
extent as compared with rings treated with L - N A M E (Fig. 5.1b). In contrast, indomethacin (3 
fimol/L) was without an effect on bradykinin-induced relaxation (Fig. 5.1c). Combined 
treatment with L - N A M E plus O D Q , C T X plus apamin eliminated the relaxant response to 
bradykinin (Fig. 5.Id). 
5.4.2. Effect of Raloxifene on Bradykinin-induced Relaxation 
In U46619-precontracted rings, bradykinin induced relaxant effects. Raloxifene (3 
nmol/L) enhanced the bradykinin-induced relaxation in rings with endothelium (Fig, 5.2a&b). 
The two consecutive bradykinin concentration-relaxation curves were superimposed with 
pECso of 7.94 士 0.19 and 7.98 土 0.11, respectively, for the first and second responses {P > 
0.05, Fig. 5.3a&b). Brief exposure (30 min) of rings with endothelium to nanomolar 
concentrations of raloxifene augmented bradykinin-induced relaxation (pECso： 8.15 士 0.10 in 
control and 8.50 士 0.11 in 1 nmol/L raloxifene, P < 0.05，Fig. 5.3c&d; 7.96 土 0.10 in control 
and 8.31 士 0.07 in 3 nmol/L raloxifene, P < 0.05, Fig. 5.3e&f)- Raloxifene at 1 or 3 nmol/L 
had no effect on baseline tone or U46619-induced vessel tension. In contrast, higher 
concentrations of raloxifene (> 1 \xmo\/L) caused endothelium-independent relaxation in the 
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same artery preparations (pECso： 4.61 士 0.16 with endothelium and 4.49 士 0.16 without 
endothelium, n=6, P > 0.05) (data not shown). 
Raloxifene enhancement (Fig. 5.4a) of bradykinin-induced relaxation was inhibited by 
ICI 182,780, a classical estrogen receptor antagonist (Fig. 5.4b). 
Bradykinin-mediated relaxation involves both endothelium-derived N O and E D H F . In 
order to elucidate which component was affected by raloxifene, the relaxation was obtained in 
rings treated with L - N A M E plus O D Q (to abolish the N O effect) or with C T X plus apamin (to 
abolish the E D H F effect). Co-treatment with L - N A M E plus O D Q reduced bradykinin-
mediated relaxation (Fig. 5.5a); under this condition, raloxifene (3 nmol/L) no longer 
potentiated the relaxation (pD2： 7.94 ±0.19 with raloxifene and 8.03 土 0.20 with raloxifene in 
L - N A M E plus O D Q , P > 0.05, Fig. 5.5a). L-NAME/ODQ-sensitive relaxation to bradykinin 
was identical in control and in the presence of raloxifene (Fig. 5.5c). However, in rings treated 
with C T X plus apamin, raloxifene (3 nmol/L) was still able to enhance bradykinin-mediated 
relaxation as reflected by a significant increase in CTX/apamin-sensitive relaxation in 
raloxifene-treated rings (P < 0.05, Fig. 5.5b&d). 
5.4.3. Effect of Raloxifene on Relaxation Induced by Substance P and A23187 
Both Substance P (receptor-dependent, Fig. 5.6a) and A23187 (receptor-independent, 
Fig. 5.6b) caused relaxation in isolated porcine coronary arteries and the relaxations were 
absent upon removal of a functional endothelium (data not shown). Treatment with raloxifene 
(3 nmol/L) for 30 min enhanced the relaxation to bradykinin, and this effect was inhibited by 
ICI 182,780 (1 i^mol/L) (Fig. 5.6a). In contrast, raloxifene did not affect relaxation to A23187, 
a calcium ionophone in the same preparations (Fig. 5.6b). 
5.4.4. Effect of Estradiol on Bradykinin-induced Relaxation 
Traces in Fig. 5.7 show a potentiating effect of estradiol on bradykinin-induced 
relaxation in rings with endothelium. Fig. 5.8a shows two identical concentration-response 
curves for two consecutive additions of bradykinin. Like raloxifene, acute treatment with low 
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concentrations of estradiol (3-10 nmol/L) also augmented bradykinin-induced relaxation in 
porcine coronary arteries (Fig. 5.8b). The estradiol-induced potentiation in relaxation to 
bradykinin was abolished by treatment with 1 )amol/L ICI 182,780 (Fig. 5.8c). Whilst ICI 
182,780 (1 |imol/L) alone did not influence bradykinin-induced relaxation (Fig. 5.8d). 
5.4.5. Effect of Raloxifene on Sodium Nitroprusside-Induced Relaxation 
In contrast, treatment with 3 nmol/L raloxifene did not modulate endothelium-
independent relaxation to sodium nitroprusside (pZ)2： 6.50 士 0.17 in control and 6.65 士 0.20, 
n=6, P > 0.05, Fig. 5.9). O D Q at 3 ^imol/L abolished N O donor-mediated relaxation (n=5， 
data not shown). These data indicated that raloxifene did not modulate NO-mediated cyclic 
GMP-dependent effect on vascular smooth muscle cells. 
5.4.6. Free Radical Scavenging Effect 
As compared with a known antioxidant, vitamin E, raloxifene but not estradiol 
exhibited a small free radical-scavenging activity when their concentrations were 1000-fold 
higher than that used to potentiate bradykinin-induced relaxation in porcine coronary arteries 
(Fig. 5.10). 
5.4.7. Raloxifene Augmentation of Bradykinin-Stimulated Endothelial 
Endothelial increase is believed to serve as an early trigger in agonist-induced 
endothelium-dependent vasodilatation. In order to examine whether raloxifene could 
potentiate bradykinin-induced increase in endothelial two consecutive stimuli were 
applied with an interval of 30 min. Since the second response to bradykinin was much smaller 
than the first one, probably due to tissue desensitization, two different agonists, substance P 
and bradykinin, were sequentially used to stimulate rises in endothelial [Ca^^], (Fig. 5.11a). 
The ratio of the second bradykinin response (the integral area under the curve) to the first 
substance P (the reference agonist) response was calculated. Treatment with 3 nmol/L 
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raloxifene did not affect bradykinin-stimulated rise in endothelial (P > 0.05，Fig. 
5.11b&c). Both agonists did not trigger a significant increase in endothelial [Ca^^Jj in a Ca^^-
free perfusion medium (data not shown). 
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Fig. 5.1. (a) Bradykinin-induced relaxation in porcine coronary arteries with and without 
endothelium, and effect of L - N A M E or O D Q . (b) Effect of charybdotoxin (CTX) plus apamin 
on relaxation to bradykinin in rings with endothelium, (c) Lack of effect of indomethacin on 
bradykinin-induced relaxation in rings with endothelium, (d) Abolition of bradykinin-induced 
relaxation in rings with endothelium following combined treatment with L - N A M E , O D Q , 
charybdotoxin (CTX) plus apamin. Results are mean 土 S.E.M.s of 4-5 experiments. * P < 0.05 
between control curve and treatment curves. 
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Fig. 5.2. Traces showing two consecutive bradykinin-induced relaxations in isolated porcine 
coronary arteries in control (a) and in the presence of 3 nmol/L raloxifene (b) before repeating 
the second concentration-relaxation curve for bradykinin. Scale bars apply to all traces. 
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Fig. 5.3. T w o consecutive concentration-response curves (CRC) for bradykinin-induced 
relaxation in U46619-precontracted isolated porcine coronary arteries in control (a), in the 
presence of 1 nmol/L (c) or 3 nmol/L (e) raloxifene (Rf). pECso values for bradykinin 
relaxation in the absence and presence of raloxifene (b,d，f). Results are mean 土 S.E.M.s of 6-8 
experiments. * P < 0.05. 
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Fig. 5.4. The effect of 3 nmol/L raloxifene (Rf) on bradykinin-induced relaxation in the 
absence (a) and presence of ICI 182,780 (ICI, b). The results are mean 士 S.E.M.s of 6-8 
experiments. * P < 0.05 between Rf and other groups. ICI, ICI 182,780. 
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Fig. 5.5. Effect of 3 nmol/L raloxifene (Rf) on bradykinin-induced relaxation in the absence 
and presence of treatment with L - N A M E plus O D Q (a) or with C T X plus apamin (b). L-
N A M E / O D Q (c)- or CTX/apamin (d)-sensitive component of bradykinin relaxation. The 
results are mean 土 S.E.M.s of 6 experiments. < 0.05 between control and Rf groups (two-
way A N O V A ) , 
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Fig. 5.6. (a) Inhibition by ICI 182,780 on the enhancing effect of raloxifene (3 nmol/L) on 
substance P-induced relaxation, (b) Lack of effect of raloxifene on A23187-induced 
relaxation. The results are mean 土 S.E.M.s of 6-8 experiments. * P < 0.05 between Rf and 
other groups. ICI, ICI 182,780. 
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Fig. 5.7. Traces showing two consecutive bradykinin-induced relaxations in isolated porcine 
coronary arteries in control (a) and in the presence of 3 nmol/L estrogen (b) before repeating 
the second concentration-relaxation curve for bradykinin. Scale bars apply to all traces 
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Fig. 5.8. (a) T w o identical concentration-response curves to bradykinin in rings with 
endothelium, (b) Enhancing relaxation to bradykinin in the presence of 3 or 10 nmol/L 
estradiol (E2). (c) Abolition by ICI 182,780 of estrogen-induced enhanced relaxation to 
bradykinin. (d) Lack of effect of ICI 182,780 alone on bradykinin-induced relaxation. The 
results are mean 士 S.E.M.s of 5-7 experiments. < 0.05 between control and estrogen groups 
(two-way A N O V A ) . 
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Fig. 5.9. Lack of effect of 3 nmol/L raloxifene (Rf) on sodium nitroprusside (SNP)-induced 
relaxation in rings without endothelium. The results are mean 土 S.E.M.s of 6-7 experiments. 
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Fig. 5.10. The free radical-scavenging activity of raloxifene (a), estradiol (estrogen, b) , and 
vitamin E (c). Results are mean 士 S.E.M.s of 6 experiments. 
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Fig. 5.11. Averaged traces from 4 determinations showing the increased [Ca^ J^i in situ by 
substance P (SP) and bradykinin (BK) in cut-open rings with endothelium (a&b). (c) Ratio of 
BK- over SP-stimulated rise in endothelial in the absence and presence of raloxifene (3 
nmol/L). Results are mean 士 S.E.Ms of 4 experiments from different pigs. N.S., not 
significant. 
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5.5, Discussion 
This study demonstrates that, in porcine coronary arteries, raloxifene enhances 
endothelium-dependent relaxation to bradykinin without affecting endothelium-independent 
relaxation to sodium nitroprusside in concentrations (1-3 nmol/L) that approximate the plasma 
raloxifene level detected in patients taking an oral daily dose of 60 m g (Snyder et al., 2000; 
Morello et al., 2003). The main findings include: (i) raloxifene improvement of endothelial 
function was antagonized by ICI 182,780, a classical estrogen receptor antagonist; (ii) 
raloxifene enhanced N O - but not EDHF-mediated relaxation to bradykinin; (iii) raloxifene did 
not affect bradykinin-stimulated increases in endothelial in freshly isolated arteries 
with endothelium; and (iv) estrogen at low concentrations also enhanced bradykinin-induced 
relaxation, which is also sensitive to inhibition by ICI 182,780. 
Bradykinin-induced relaxation is mediated by N O and E D H F derived in the 
endothelium and this relaxation was eliminated after combined treatment with L - N A M E (a 
N O S inhibitor) and C T X plus apamin (the inhibitors of EDHF). The enhancing effect of 
raloxifene on bradykinin-induced relaxation was absent after exposure of rings to L - N A M E 
plus O D Q (a guanylate cyclase inhibitor). In contrast, the effect of raloxifene was unaltered by 
treatment with C T X plus apamin. Estradiol potentiates bradykinin-induced endothelium-
dependent relaxation in isolated human coronary arteries but in a supra-physiological 
concentration (3 ^imol/L) (Barton et al,, 1998). It is, however, unknown which component of 
bradykinin-mediated relaxation is augmented by estradiol. The present results indicate that 
raloxifene enhances bradykinin-mediated vascular action likely through enhancing release or 
bioavailability of N O in the endothelium. Besides, the present study shows that estradiol in 
mean physiological concentrations (3-10 nmol/L) also potentiated relaxation to bradykinin and 
this potentiation was antagonized by ICI 182,780. 
The potentiating effect of raloxifene is not confined to bradykinin-induced relaxation. 
Raloxifene (3 nmol/L) also augmented the relaxations to substance P, another receptor-
mediated endothelium-dependent vasodilator. In contrast, raloxifene did not influence the 
endothelium-dependent relaxations to A23187 (a receptor-independent dilator and a calcium 
ionophone). 
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Clinical studies reveal that raloxifene therapy influences endothelial function and 
improves flow-mediated dilation in healthy menopausal w o m e n (Sarrel et al., 2003; Saitta et 
al., 2001), and intra-arterial infusion of the N O S inhibitor N^-nitro-L-arginine inhibits the 
effect of raloxifene (Colacurci et al, 2003). However, this benefit was not observed in patients 
with coronary artery disease (Griffiths et al., 2003). It appears that the healthy endothelium is 
required for the improved endothelial function by raloxifene. Raloxifene (> 10 nmol/L) causes 
rapid action of endothelial N O S in human endothelial cells in a non-genomic manner 
(Simoncini et al., 2002). Although it is unproven, this effect may partly account for vascular 
benefits of chronically administered raloxifene. 
The biosynthesis of N O by e N O S from its precursor L-arginine is a Ca^^-dependent 
process. Various endothelial NO-dependent vasodilators stimulate N O release by increasing 
endothelial The present study demonstrated that raloxifene at 3 nmol/L, a 
concentration that enhanced endothelium-mediated relaxation to bradykinin, did not alter 
bradykinin-stimulated rise in [Ca^+Jj in native endothelial cells of intact coronary arteries. 
Thus, the increased Ca^^ influx is unlikely to be involved in the augmented N O function 
mediated by raloxifene. 
In addition to enhanced synthesis and/or release of N O , it is also possible that another 
mechanism for increased N O function may involve the antioxidant properties of estrogenic 
agents (Amal et al., 1996). Blood pressure reduction after bradykinin infusion was more 
pronounced in hypertensive rats treated with raloxifene; the increased activity of endothelial 
N O S was accompanied by a reduced production of reactive oxygen species in vascular cells 
(Wassmann et al., 2002). However, raloxifene at concentrations up to 1 |amol/L did not exhibit 
significant free radical scavenging activity compared with vitamin E. It is therefore unlikely 
that raloxifene could acutely protect N O from scavenging by reactive oxygen species. 
In summary, the present study demonstrates that in isolated porcine coronary arteries, 
acute exposure to therapeutically relevant concentrations of raloxifene augments bradykinin-
induced endothelial NO-mediated relaxation, which is unlikely to be associated with 
rises in the endothelium, and this effect is sensitive to antagonism of the estrogen receptors. 
Improved endothelial (NO) function would contribute to the potential cardioprotective effect 
of raloxifene even though we cannot attribute this observation with certainty to an in vivo 
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condition. Finally, these data suggest that the endothelium represents an important target site 
for positive vascular effects exerted by raloxifene in the coronary circulation. 
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CHAPTER VI 
Cilnidipine, a Slow-Acting Ca^ ^ Channel Blocker, Induces 
Relaxation in Porcine Coronary Arteries: Role of Endothelial 
Nitric Oxide and [Ca^+h 
6.1. Abstract 
Cilnidipine is a dual blocker of L-type voltage-gated Ca^^ channels in vascular smooth 
muscle and N-type Ca^^ channels in sympathetic nerve terminals that supply blood vessels. 
However, the clinical benefits of cilnidipine and underlying mechanisms are incompletely 
understood. This study was designed to compare the time course of relaxant responses to 
cilnidipine and nifedipine, and to examine the role of endothelial N O and in the 
vasorelaxation. The porcine left circumflex coronary arteries were isolated, and isometric 
tension was measured with Grass force transducer. Endothelial in intact arteries was 
determined by calcium fluorescence imaging technique. The free radical scavenging activity 
of cilnidipine and nifedipine were also assayed. 
Both cilnidipine and nifedipine induced concentration-dependent relaxations in high 
K^-precontracted artery rings. The onset of cilnidipine action was slower when compared with 
nifedipine. Treatment with L - N A M E or O D Q reduced relaxations to cilnidipine or nifedipine 
to the same extent as those obtained in endothelium-denuded rings. Indomethacin or co-
conotoxin had no effects. L-Arginine antagonized the effect of L - N A M E on cilnidipine-
induced relaxation. Cilnidipine did not affect sodium nitroprusside-induced relaxation in rings 
with and without endothelium. 
Cilnidipine and nifedipine caused extracellular Ca^^-dependent increases in endothelial 
[Ca2+]i in intact arteries and cilnidipine action had a slower onset, similar to the onset of 
cilnidipine-induced relaxation. Neither cilnidipine nor nifedipine exhibited significant free 
radical scavenging property. 
These results demonstrate that cilnidipine can produce endothelium-dependent 
relaxation in porcine coronary arteries in vitro in addition to blocking Ca^^ channels. Like 
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short-acting nifedipine, cilnidipine-dependent relaxation albeit to a slower onset is partly 
mediated by endothelial N O but not prostacyclin. The increased release or bioavailability of 
N O may causally result from elevated endothelial [Ca^^Ji in endothelium-intact arteries. The 
Ca2+ channel-independent effect suggests the usefulness of cilnidipine in the treatment of 
cardiovascular diseases associated with diminished N O release, such as atherosclerosis. 
6.2. Introduction 
Dihydropyridine (DHP) calcium antagonists, including nifedipine, are frequently used 
in the treatment of hypertension, stable angina pectoris, and cerebrovascular disease in humans 
by blocking L-type voltage-gated Ca^^ channels. These therapeutic agents relax coronary 
arteries, cause peripheral vasodilatation, and decrease left ventricular contraction, thereby 
reducing the myocardial oxygen demand. Clinical studies and meta-analysis, however, have 
questioned the long-term safety of nifedipine regimen that actually increases the risk of 
myocardial infarction and mortality in patients with coronary artery disease (Furberg et al., 
1995； Psaty et al., 1995; Stason et al., 1999). The deleterious mechanism for this fatal adverse 
effect of nifedipine is unclear. Rapid hypotensive action of short-acting D H P s causes an 
elevation in vascular sympathetic tone and reflex tachycardia. The increased release of 
noradrenaline may represent a coronary risk factor in hypertensive patients (Julius, 1993). 
In contrast to nifedipine, which is a short-acting generation DHP, exclusively blocks 
L-type Ca2+ channels, cilnidipine is a new, long-acting generation D H P that blocks both L-
and N-type Ca^^ channels. Cilnidipine is a slow-onset vasodilator and antihypertensive drug as 
shown in clinical and animal studies (Yoshimoto et al., 1991; Tominaga et al., 1997). 
Cilnidipine blocks L-type Ca^^ channels in vascular smooth muscle cells at concentrations that 
do not inhibit protein kinase C (PKC) (Lohn et al., 2002), while nifedipine is a potent inhibitor 
of P K C (Hempel et al., 1999). Besides, cilnidipine also inhibits T-type Ca^^ currents in guinea 
pig ventricular myocytes (Takeda et al., 2004). 
Cilnidipine attenuates vascular sympathetic neurotransmission (Hosono et al., 1995) 
probably by inhibiting the N-type Ca^ "^  channels (Fujii et al,, 1997). With this unique dual 
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L/N-type blocking property, cilnidipine may have clinical advantages over nifedipine with 
respect to cardiovascular protection. Indeed, cilnidipine effectively lowers blood pressure with 
significantly less influence on heart rate and sympathetic nerve activity than nifedipine in 
hypertensive patients (Minami et al., 1998; 2000). Cilnidipine is also demonstrated to reduce 
blood pressure in animal studies (Nakajima et al., 2002; Varagic et al., 2002). 
The endothelium regulates the vascular tone and blood pressure. Endothelial 
dysfunction characterized by impaired endothelium-dependent vasodilatation has been 
described in both human and animal hypertension (Mombouli & Vanhoutte，1999). Some 
D H P S exhibit Ca^^ channel-independent vascular effects leading to an improvement of 
endothelial function (Taddei et al., 1997b; Krenek et al., 2001). Recent in vitro studies have 
shown that nifedipine enhances N O release via up-regulation of e N O S expression (Ding & 
Vaziri, 2000) and possesses antioxidant or free radical scavenging effects (Lesnik et al., 
1997). 
As compared to nifedipine, however，it is unknown whether cilnidipine exerts similar 
beneficial effects on the endothelium by releasing vasorelaxing substances. In this study, we 
tested the hypothesis that cilnidipine produces endothelium-dependent relaxation in porcine 
coronary arteries in vitro in addition to its known Ca^^ channel-blocking property. 
Specifically, w e examined (i) whether cilnidipine acutely induces endothelium-dependent 
relaxation and what endothelium-derived vasoactive factors are involved, (ii) whether 
cilnidipine stimulates an increase in endothelial [Ca2+]i in situ in freshly isolated endothelium-
intact artery rings, and (iii) whether cilnidipine possesses a free radical-scavenging property. 
For comparison, w e studied the arterial effects of nifedipine, the clinically relevant prototype 
of the D H P calcium antagonists in the same preparations. 
6.3. Methods and Materials 
6.3.1. Vessel Preparation 
All experiments were performed in accordance with institutional guidelines. This 
investigation conformed to the Guide for the Care and Use of Laboratory Animals published 
by the U S National Institute of Health (NIH Publication No. 85-23, revised 1996). Fresh pig 
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hearts were obtained from a local slaughterhouse in Hong Kong. The hearts were placed on a 
dissecting plate containing ice-cold Krebs solution. Krebs solution contained (in mmol/L): 
NaCl 119, KCl 4.7, CaCli 2.5, MgCli l，NaHC03 25, KH2PO4 1.2, and D-glucose 11. After fatty 
connective tissues were trimmed off, each left circumflex coronary artery was cut into several 
ring segments of 3 m m in length. Each ring was mounted in an organ bath. The bathing 
solution was continually oxygenated with 95% O2 - 5 % CO2 and maintained at 37 (pH: 7.3 
-7.5). The ring was stretched to the optimal tension of 15 m N and then allowed to equilibrate 
for about 90 min before the start of the experiment. In some rings, the endothelial layer was 
removed by gently rubbing the luminal surface with forceps. Removal of the functional 
endothelium was confirmed by lack of a relaxant response to 50 nmol/L bradykinin. Each 
experiment was performed on rings prepared from different pigs. 
6.3.2. Isometric Force Measurement 
Thirty minutes after setting up in organ baths, each ring was initially contracted by 30 
nmol/L U46619 and subsequently relaxed by 50 nmol/L bradykinin to confirm the presence of 
the endothelium. Rings were then washed in pre-warmed Krebs solution until baseline tone 
was restored. High K+ solution was prepared by substituting an equivalent amount of NaCl 
with KCl in order to maintain constant ionic strength. 
The first series of experiments examined the relaxant effects of different 
concentrations of cilnidipine (3-100 nmol/L) or nifedipine (3-100 nmol/L) in 60 mmol/L KCl-
precontracted rings with endothelium. The relaxant responses were allowed to reach a steady-
state level. The second set of experiments used 30 mmol/L KCl solution, an ionic condition 
that eliminates the involvement of endothelium-derived hyperpolarizing factors (EDHF) in 
porcine coronary arteries. Since a small relaxation induced by bradykinin in 30 mmol/L K+-
contracted rings with endothelium was abolished by L - N A M E (a N O S inhibitor), this part of 
relaxation is attributable to N O . Since reduced relaxations to both D H P agents in the absence 
of endothelium were observed, the role of endothelium-derived N O or prostacyclin was 
studied. Rings with endothelium were incubated for 30-min with L - N A M E (100 fimol/L), 
O D Q (an inhibitor of guanylate cyclase, 3 fimol/L), or indomethacin (an inhibitor of 
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prostacyclin biosynthesis, 3 ^imol/L), or co-conotoxin (a N-type Cd^^ channel blocker, 100 
nmol/L) prior to application of 30 mmol/L K C L Once steady tone was obtained, cilnidipine or 
nifedipine (each at 30 nmol/L) was added to induce relaxation. In order to test whether 
treatment with L-arginine could antagonize the effect of L - N A M E , rings with endothelium 
were exposed to L-arginine (500 j^mol/L) for 10 min before the addition of L - N A M E . The last 
group of experiments examined the relaxant effects of cilnidipine and nifedipine in L - N A M E -
treated rings without endothelium. The role of the endothelium in DHP-induced relaxation 
was also examined in rings contracted by 60 mmol/L K C L The presence of endothelium did 
not affect high KCl-induced vessel tone (30 mmol/L contraction: 3.59 士 0.28g with 
endothelium and 3.55 士 0.20g without endothelium, P > 0.05; 60 mmol/L contraction: 4.17 士 
0.29g with endothelium and 4.13 ± 0.26g without endothelium, P > 0.05). 
Effects of cilnidipine (10 nmol/L, 30-min exposure) were tested on endothelium-
independent relaxation to N O donor, sodium nitropmsside (200 ^imol/L) in the presence and 
absence of endothelium. 
6.3.3. In situ Endothelial [Ca^'h Imaging 
Porcine circumflex coronary artery rings were labeled fluorescently by incubation with 
10 i^mol/L of Fura-2 A M , 0.025% pluronic F-127 and 1 mmol/L probenacid (to prevent Fura-
2 secretion) in Krebs solution for 1 hr at 22 Extracellular Fura-2 A M was washed away in 
Krebs solution. The vessel rings were then perfused for 20-min with Krebs solution at a rate (2 
ml/min) at 37 °C to permit intracellular esterases to cleave intracellular Fura-2 A M into active 
Fura-2. 
The basic setup for endothelial [Ca ]i imaging was modified as first described by 
Huang et al., (Huang et al., 2000). Briefly, after the Fura-2 loading, the rings were 
longitudinally cut open and pinned down onto a block of silicone elastomer, which was fixed 
onto a base plate of the custom-made flow chamber. The base plate was then covered with a 
gasket and cover glass (24 m m X 32 mm), and affixed by screws. There was a 1-mm gap 
between the vessel lumen and cover glass for flow passage. After mounting, the flow chamber 
was placed on an inverted microscope and perfused with Krebs solution at 37 °C at a constant 
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rate of 2 ml/min maintained by a six-channel perfusion pump. The specimen was illuminated 
on the stage of the 1X70 Olympus microscope, fitted with a 20X Olympus water immersion 
objective by using a Polychrome IV light source. Fura-2 loaded vascular tissues were 
alternatively excited at 340 and 380 nm, and images of the respective 510-nm emissions were 
collected at every 1-second interval using MetaFluor v4.6 software (Universal Imaging Corp., 
USA). The emitted light was transmitted to the collecting device and then to a cooled charge 
coupled device (CCD) camera. Illumination through the Polychrome IV light source and 
acquisition by the C C D camera were controlled by MetaFluor software v4.6. Video frames 
containing images of cell fluorescence were digitized at a resolution of 512 horizontal X 480 
vertical pixels. Imaging analysis was also performed with a MetaFluor imaging system 
(Universal Imaging Corp.). After background subtraction, the fluorescence ratio (F340/F380) 
was obtained by dividing, pixel by pixel, the 340 n m image by the 380 n m image. Changes in 
this ratio reflected changes in to eliminate potential artifacts caused by variations in 
cell thickness, intracellular dye distribution or photobleaching. 
6.3.4. Free Radical Scavenging Assay 
Possible free radical scavenging properties of D H P s were examined as previously 
described (Blois, 1958). a-Tocopherol (vitamin E) was used as a reference antioxidant. In 
brief, 0.5 m L of methanol containing different concentrations (10-1000 nmol/L) of D H P s was 
mixed in a test tube with 2.5 m L of methanol containing 75 ^imol/L 2,2-diphenyl-l-
picrylhydrazyl (DPPH). D P P H is a stable free radical with a deep purple color in ethanotic 
solution and a typical absorbance at 517 nm, but becomes pale yellow when trapped by an 
antioxidant. The reaction mixture was kept in dark at room temperature for 90 min and the 
absorbance at 517 n m was thereafter measured. The free radical scavenging activity was 
approximated using the following equation: 
D P P H scavenging activity (%) = [Aa-(Ab-Ac)]/Aa x 100 
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where i4a is the absorbance of the incubation D P P H solution without D H P , A\) is the 
absorbance of the incubation mixture containing D P P H and D H P , and A^ is the absorbance of 
the blank solution (methanol) with DPPH. 
6.3.5. Chemicals 
Bradykinin, U46619, L - N A M E , O D Q , L-arginine, indomethacin, nifedipine, co-
conotoxin, sodium nitroprusside, D P P H were purchased from Sigma. Cilnidipine was a gift 
from Fujirebio (Tokyo, Japan). Stock solution was prepared in D M S O for D H P s and kept at — 
20 Desired dilution was made before experiments. D M S O (0.1% v/v) did not cause 
vasorelaxation. 
6.3.6. Data Analysis 
Results are mean 士 S.E.Ms and n refers to the number of pigs. Several rings prepared 
from the same artery were studied in parallel. Time-dependent relaxant effects of D H P s were 
investigated after various pharmacological interventions. The relaxation was expressed as 
percentage reduction in high KCl-induced tone and relaxation curves were analyzed and time 
(^ 1/2) required for producing 50% of the maximal relaxation was calculated using Graphpad 
software (Version 3.0). Time-dependent relaxation curves were analyzed by two-way 
A N O V A followed by Bonferroni post-tests. P values of less than 0.05 was regarded as 
statistically significant. 
6.4. Results 
6.4.1. Relaxant Responses 
Both cilnidipine and nifedipine relaxed 60 mmol/L KCl-contracted rings with 
endothelium in a concentration-dependent manner (Fig. 6.1a&c). There was little difference in 
relaxing potency of both blockers as determined by steady-state relaxation (Fig. 6.1b&d). The 
onset of relaxation was, however, much faster for nifedipine than cilnidipine at each 
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concentration tested (Fig. 6.1a&c). Nifedipine at 100 nmol/L induced a rapid relaxant 
response, which reached a steady-state peak effect within 10-min after drug application (Fig. 
6.1c). In contrast, cilnidipine at the same concentration induced slowly developing relaxation 
and the steady-state m a x i m u m effect was obtained 80-min after drug application (Fig. 6.1a). 
Fig. 6.1e summarizes the t\n values for relaxations induced by both DHPs. 
6.4.2. Role of the Endothelium 
In 30 mmol/L K^-contracted rings with endothelium, cilnidipine at 30 nmol/L caused 
relaxation and the peak response was obtained after 120-min and this relaxation was reduced 
significantly upon removal of the endothelium (Fig. 6.2a). Likewise, nifedipine at 30 nmol/L 
induced less relaxant effects in rings without endothelium than in rings with endothelium (Fig. 
6.3a). 
6.4.3. Effect of Inhibitors of NO-Dependent Relaxation 
Treatment of rings with endothelium by L - N A M E (Fig. 6.2b) or O D Q (Fig. 6.2c) 
attenuated cilnidipine-induced relaxation. L - N A M E and O D Q reduced cilnidipine-dependent 
relaxation to a similar extent as seen in rings without endothelium. Preincubation with L-
arginine, the precursor of N O biosynthesis almost abolished the inhibitory effect of L - N A M E 
(Fig. 6.2b&d). Likewise, L - N A M E and O D Q reduced relaxation induced by nifedipine (30 
nmol/L) and L-arginine antagonized the effect of L - N A M E (Fig. 6.3b&c). In contrast, L-
N A M E did not affect the relaxations to cilnidipine or nifedipine in rings without endothelium 
(n=5, data not shown). Relaxation induced by cilnidipine or nifedipine in 60 mmol/L KCl-
contracted rings was the same in the presence and absence of the endothelium (Fig. 6.4). 
Bradykinin (50 nmol/L) induced only a small relaxation (21.2 士 4.6o/o) in 30 mmol/L KCl-
contracted rings with endothelium, which was abolished by treatment with 100 fimol/L L-
N A M E , and bradykinin did not relax 60 mmol/L KCl-contracted rings with endothelium (Fig. 
6.5). 
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6.4.4. Effect of Indomethacin and CD-Conotoxin 
Indomethacin did not modify relaxations to cilnidipine or nifedipine (Fig. 6.6), thus 
ruling out the involvement of relaxing prostanoids in the endothelium-dependent effects for 
both DHPs. co-Conotoxin (100 nmol/L) did not affect 30 mmol/L KCl-induced tone nor 
cilnidipine-induced relaxation (n=5) (data not shown). 
6.4.5. Effect of Cilnidipine on Sodium Nitroprusside-Induced Relaxation 
Cilnidipine (10 nmol/L, 30-min incubation) inhibited 30 mmol/L KCl-induced 
contraction of rings with endothelium (3.58 ± 0.28 g in control and 2.10 士 0.32g in 
cilnidipine). However, cilnidipine did not affect the relaxations to 200 ^imol/L sodium 
nitroprusside in the presence and absence of endothelium (Fig. 6.7). 
6.4.6. Effects on Endothelial in Isolated Endothelium-Intact Coronary Arteries 
Fluorescence images from individual living endothelial cells in intact cut-open rings 
were clearly visible and signals were absent upon removal of the endothelium. A n increase in 
[Ca2+]i was induced by bradykinin only in endothelium-intact arteries (Fig. 6.8a). Fig. 6.8b 
shows that perfusion of 30 nmol/L cilnidipine caused a slow increase in [Ca^ ]^；. The increase 
in [Ca2+]i was long-lasting (80-min) and completely abolished in the absence of extracellular 
Ca2+ (plus 300 lamol/L Na2-EGTA). Likewise, addition of 30 nmol/L nifedipine induced a 
similar but faster effect in raising endothelial [Ca2+]i which was also dependent on the 
O丄 _ _ 
presence of extracellular Ca ions (Fig. 6.8c). 
6.4.7. Free Radical Scavenging Effect 
As compared with a known antioxidant, vitamin E, cilnidipine and nifedipine (1 - 100 
nmol/L) that relaxed porcine coronary arteries did not possess significant free radical-
scavenging activity as shown in Fig. 6.9. 
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Fig. 6.1. Concentration-dependent relaxant responses to cilnidipine (a) or nifedipine (c) in 60 
mmol/L KCl-contracted porcine coronary artery rings with endothelium. The percentage 
relaxation recorded at 160-min (b) after application of cilnidipine (3-100 nmol/L) or at 100-
min (d) after application of nifedipine (3-100 nmol/L). (e) The time taken for cilnidipine or 
nifedipine to produce half 好）of the maximal relaxant effect and 95% confidence intervals for 
ti/, are indicated in parentheses at the top of each column. Results are mean 士 S.E.Ms of 6-7 
experiments. Statistical difference from the control is indicated by ** P < 0.01, *** P < 0.001 
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Fig. 6.2. Reduced relaxation to 30 nmol/L cilnidipine in rings without endothelium compared 
to rings with endothelium (a). Attenuated cilnidipine-induced relaxation following treatment 
with L - N A M E (b) or O D Q (c) in rings with endothelium. Treatment with L-arginine reversed 
the effect of L - N A M E (b). The relaxant effect recorded at 30-min after application of 
cilnidipine (d). All these experiments were performed on 30 mmol/L K+-contracted rings. 
Statistical difference is indicated by a between treatment and control groups and by b between 
treatment and L - N A M E groups (* P < 0.05, ** P < 0.01). Results are mean 土 S.E.Ms of 6-8 
experiments. 
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Fig. 6.3. Reduced relaxation to 30 nmol/L nifedipine in rings without endothelium compared 
to rings with endothelium (a). Attenuated nifedipine-induced relaxation in the presence of L-
N A M E (b) or O D Q (c) in rings with endothelium. Treatment with L-arginine reversed the 
effect of L - N A M E (b). The relaxant effect recorded at 30-min after application of nifedipine 
(d). All these experiments were performed on 30 mmol/L K+-contracted rings. Statistical 
difference is indicated by a between treatment and control groups and by b between treatment 
and L - N A M E groups (* P < 0.05, *** P < 0.001). Results are mean 士 S.E.Ms of 6-8 
experiments. 
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Fig. 6.4. Lack of influence of the endothelium on relaxation to 30 nmol/L cilnidipine (a) or 30 
nmol/L nifedipine (b) in 60 mmol/L K+-contracted rings. Results are mean 士 S.E.Ms of 5 
experiments. 
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Fig. 6.5. Inhibitory effect of 100 |imol/L L - N A M E on relaxation to 50 nmol/L bradykinin in 
30 mmol/L KCl-contracted rings with endothelium (a) and failure of bradykinin to relax 60 
mmol/L KCl-contracted rings with endothelium (b). Results are mean 士 S.E.Ms of 5 
experiments. 
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Fig. 6.6. Lack of effect of indomethacin on relaxation to 30 nmol/L nifedipine (a) or 30 
nmol/L cilnidipine (b) in 30 mmol/L KCl-contracted rings with endothelium. Results are mean 
士 S.E.Ms of 6 experiments. 
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Fig. 6.7. Lack of effect of cilnidipine (10 nmol/L, 30-min incubation) on relaxation to 200 
fimol/L sodium nitroprusside in 30 mmol/L KCl-contracted rings with and without 
endothelium. Results are mean 士 S.E.Ms of 5 experiments. 
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Fig. 6.8. The stimulatory effects of cilnidipine (30 nmol/L, a&b) and nifedipine (30 nmol/L, c) 
on endothelial calcium levels in situ in cut-open rings with endothelium. Results are mean 士 
S.E.Ms of 4-5 experiments from different pigs (*P< 0.05). 
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Fig. 6.9. The free radical scavenging activity of DHPs, cilnidipine (a), nifedipine (b), and 
vitamin E (c). Results are mean 士 S.E.Ms of 6 experiments. 
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6.5. Discussion 
It is known that some D H P s can augment N O release from endothelial cells either in 
cultured cells or intact non-coronary arteries (Zhang & Hintze, 1998; Berkels et al., 2001a) 
probably through up-regulation of e N O S protein (Ding & Vaziri, 2000) or antioxidation 
(Berkels et al., 2001). The main findings in this study are summarized as follows: (i) porcine 
coronary artery relaxations to cilnidipine and nifedipine are partly endothelium-dependent and 
involving NO/cyclic G M P signaling, (ii) the onset of cilnidipine action is much slower when 
compared with that of nifedipine, but both D H P s showed similar relaxing potency, (iii) like 
nifedipine, cilnidipine raises intracellular calcium concentration in native endothelial cells in 
intact coronary arteries in situ, with similar onset as to that of cilnidipine-induced relaxation, 
(iv) neither cilnidipine nor nifedipine possesses a free radical scavenging effect. 
N O , one of the most prominent endothelium-derived regulators of arterial tone relaxes 
vascular smooth muscle cells via cyclic GMP-mediated signaling (Murad, 1994). Several 
D H P S including nifedipine (short-acting, generation) and lacidipine (long-acting, 
generation) increase N O liberation in endothelial cells and this N O release is completely 
blocked by N O S inhibitors (Ding & Vaziri, 2000; Krenek et al., 2001; Berkels et al., 2001). 
Our data clearly demonstrate that like nifedipine, cilnidipine (30 nmol/L)-induced relaxation is 
partly endothelium-dependent, and this component, which is the L - N A M E (NOS inhibitor)- or 
O D Q (guanylate cyclase inhibitor)-sensitive component, accounts for approximately 30% of 
the total relaxation. Treatment of the vessels with L-arginine prevented L-NAME-induced 
inhibition of relaxation. Furthermore, L - N A M E did not alter the relaxant effects of cilnidipine 
or nifedipine upon removal of the endothelium. Our data demonstrate that the endothelium-
dependent relaxation to cilnidipine is primarily mediated by NO/cyclic GMP-dependent 
mechanisms in porcine coronary arteries. Lack of an effect on relaxation induced by 
nitroprusside indicates that cilnidipine does not interact with NO-mediated signaling pathway. 
The endothelium-dependent relaxation to either cilnidipine or bradykinin was observed only in 
30 mmol/L K+_ but not in 60 mmol/L K+-contracted rings. High K+-induced contractions were 
comparable in rings with and without endothelium, suggesting that the endothelium is unlikely 
to contribute tonically to DHP-induced relaxation. The present results also indicate that the 
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claimed N-type Ca^^ channel blocking activity in sympathetic nerves does not influence 30 
mmol/L K+-induced contraction or cilnidipine-induced relaxation since co-conotoxin (a potent 
blocker of N-type Ca^^ channel on sympathetic nerves) (Brock & Cunnane, 1999) has no 
effect. 
1 
The biosynthesis of N O by eNOS from its precursor L-arginine is a Ca -dependent 
process. Various endothelial NO-dependent vasodilators stimulate N O release by increasing 
endothelial [Ca�—]” Our study demonstrates that cilnidipine, like nifedipine acutely caused an 
increase in in native endothelial cells in intact coronary arteries. The stimulatory effects 
relied completely on the presence of extracellular calcium ions. The long-lasting time course 
of increase in [Ca^ '^l (up to 80-min, Fig. 6.8) correlate well with the slow and long-lasting 
relaxation induced by cilnidipine (Fig. 6.2). Likewise, twenty minutes are required for the 
steady response to nifedipine (30 nmol/L) in both vessel tension and [Ca�.]丨(Fig. 6.3 & 6.8). 
The stimulatory effect of cilnidipine on does not appear to be related to voltage-gated 
L/N-type Ca^^ channels since these channels are not expressed in endothelial cells (Adams et 
al, 1989). 
The acute endothelium-dependent effects of nifedipine and cilnidipine may not involve 
the up-regulation of expression of eNOS m R N A and eNOS protein since nifedipine starts to 
stimulate the N O release 20 minutes after its application and prolonged treatment (48 hr) did 
not affect eNOS protein levels (Berkels et al., 2001). However, long-term treatment (5-6 
weeks) with lacidipine (Krenek et aL, 2001) or cilnidipine (Kobayashi et al., 2001) has been 
reported to up-regulate eNOS m R N A levels in hypertensive rats. Besides, chronic nifedipine 
therapy (6 months) restored coronary endothelial function in patients with coronary artery 
disease ( E N C O R E Investigators, 2003). Our data together with others suggest that the 
mechanisms underlying the acute and chronic effects of D H P s on endothelial N O function 
may be different. The former is more likely coupled to the increased endothelial [Ca^ ""], 
(Berkels et al., 1999); whereas the latter is associated with elevated eNOS expression and/or 
activity (Krenek et al., 2001; Kobayashi et al., 2001). 
Finally, various D H P calcium antagonists have been reported to possess antioxidant 
activity (Lesnik et al., 1997; Cominacini et al., 2003; Berkels et al., 2001). Nifedipine (48 hr-
treatment) increased endothelial N O bioavailability through reducing production of reactive 
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oxygen species (Berkels et al., 2001). Although we cannot exclude a possible acute 
suppression of reactive oxygen species production by cilnidipine in intact porcine coronary 
arteries, our data show that cilnidipine or nifedipine displayed little or no free radical 
scavenging effect. Therefore, the increased bioavailability of N O by scavenging the free 
radicals may not be involved in the endothelium-dependent vascular responses to cilnidipine. 
In conclusion, w e have added one additional mechanisms by which cilnidipine exerts 
its action in coronary arteries, e.g. stimulation of Ca^^-dependent N O release in endothelial 
cells, apart from its blockade of L/N-type Ca^^ channels in arterial smooth muscle and 
sympathetic nerves demonstrated by other researchers. The endothelial N O release may 
exhibit additionally antithrombotic, antiproliferative, and antiatherosclerotic effects. The N-
type Ca2+ channel blocking property of cilnidipine may offer clinical benefits by attenuating 
the reflex tachycardia due to sympathetic stimulation of the heart, a potentially fatal side-effect 
resulting from nifedipine therapy in patients with coronary artery disease (Furberg et al., 1995; 
Stason et al., 1999). Indeed, recent clinical studies show that cilnidipine is effective as a once-
daily antihypertensive drug without reflex tachycardia and increase in sympathetic nerve 
activity in essential hypertensive patients (Minami et al； 2000; Kitahara et al., 2004). It has 
yet to be determined whether the stimulatory effects of cilnidipine on endothelial N O release 
is clinically relevant, e.g. in the treatment of coronary artery disease and other chronic 
vascular diseases. 
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CHAPTER VII 
Summary 
The present study has provided novel findings revealing some mechanisms by which 
SERMs (tamoxifen and raloxifene) and DHPs (nifedipine and cilnidipine) influence the 
vascular reactivity in porcine left circumflex coronary arteries. 
Tamoxifen, the first-generation SERM, induced endothelium (NO)-dependent 
relaxation, which was mediated by ICI 182,780-sensitive estrogen receptors in the 
endothelium (Fig. 7.1). The relaxation was partly mediated through the activation of K+ 
channels in the endothelium and Na+-K+ ATPase in the vascular smooth muscle cells, the 
former was inhibited by C T X plus apamin and BaCb while the latter was inhibited by 
ouabain or by the incubation in an extracellular K+-free solution. It appears that 
tamoxifen-induced NO-dependent effect on the activity of Na+-K+ ATPase in vascular 
smooth muscle is mediated by a cyclic GMP-dependent mechanism. The stimulation of 
Na+-K+ ATPase would cause membrane hyperpolarization which in turn reduces Ca^^ 
influx via voltage-sensitive Ca^^ channels, leading to coronary artery relaxation (Fig. 7.1). 
Tamoxifen did not inhibit voltage-sensitive Ca^^ channel-dependent contraction. However, 
it remains to be investigated how ICI 182,780-sensitive estrogen receptor links to the 
activation of K+ channels in endothelium upon binding with tamoxifen. 
Treatment with therapeutic concentrations (1-3 nmol/L) of raloxifene, the 
second-generation SERM, did not cause relaxation but it augmented 
endothelium-dependent relaxation to bradykinin (Fig. 7.2) or substance P, which were 
likely to be mediated through ICI 182,780-sensitive estrogen receptors. The augmentation 
in relaxation involved agonist-induced N O production since the effect of raloxifene was 
abolished by the presence of L-NAME and ODQ, but independent of rises in 
endothelial cells. Higher concentrations (> 1 |Limol/L) of raloxifene, however, caused 
endothelium-independent relaxation (Fig. 7.2), which involved (1) inhibition of Ca^^ 
channels and the opening of K+ channels in vascular smooth muscle cells. The results of 
the present study indicate the potential use of tamoxifen and raloxifene in the treatment of 
postmenopausal cardiovascular symptoms if clinical trials confirm their long-term safety. 
Finally, the second-generation dihydropyridine calcium channel antagonist, 
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cilnidipine, induced endothelium-dependent and -independent relaxation. Cilnidipine 
stimulated a rise in [Ca^ ]^, in native endothelial cells. As compared with the effect of 
nifedipine, the first-generation Ca^ "" channel blocker which has recently been shown to 
cause sudden cardiac death in patients with coronary artery disease, caused relaxation with 
a slower onset. Due to the unique properties of blocking both L-type Ca^^ channels in 
vascular smooth muscle and N_ type Ca'^ channels blockers in sympathetic nerve endings, 
cilnidipine may offer advantages over nifedipine, particularly in patients with heart disease 
since cilnidipine shares Ca'^ channel-independent benefits of nifedipine without causing 
baroreflex-induced tachycardia as observed in nifedipine users. 
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Fig. 7.1. 
Proposed non-genomic mechanisms responsible for acute relaxation in response to 
tamoxifen in isolated porcine coronary arteries. Tamoxifen relaxes arteries by acting 
primarily on endothelium to release NO via L-NAME-, BaCb- and CTX plus 
apamin-sensitive pathways. The endothelium-derived NO then activated Na+-K+ ATPase in 
vascular smooth muscle cells, leading to coronary artery relaxation. 
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Fig. 7.2. 
Proposed mechanisms responsible for the acute effect of raloxifene on endothelium and 
vascular smooth muscle. Raloxifene at therapeutic concentrations (1-3 nmol/L) enhanced 
endothelium (NO)-dependent relaxation to bradykinin in ICI 182,780-sensitive manner. 
Higher concentrations of (> 1 jimol/L) caused direct relaxation which was independent of 
the presence of endothelium but involved (i) inhibition of voltage-sensitive Ca2+ channels 
and (ii) activation of Ca2+-activated K+ channels in vascular smooth muscle cells. 
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Proposed mechanisms responsible for cilnidipine-induced endothelium-dependent 
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